

TEKLA HEALTHCARE INVESTORS  
Form N-PX  
August 20, 2018

**UNITED STATES  
SECURITIES AND EXCHANGE  
COMMISSION**

OMB APPROVAL  
OMB Number: 3235-0582  
Expires: March 31, 2021  
Estimated average burden  
hours per response.....7.2

Washington, D.C. 20549

**FORM N-PX**

**ANNUAL REPORT OF PROXY VOTING RECORD OF REGISTERED  
MANAGEMENT INVESTMENT COMPANY**

Investment Company Act file number 811- 04889

**Tekla Healthcare Investors**

(Exact name of registrant as specified in charter)

**100 Federal Street, 19th Floor, Boston, MA**  
(Address of principal executive offices)

**02110**  
(Zip code)

**Laura Woodward**

**Tekla Healthcare Investors**

**100 Federal Street, 19th Floor, Boston MA 02110**

(Name and address of agent for service)

Registrant's telephone number, including area code: **617-772-8500**

Date of fiscal year end: **September 30**

## Edgar Filing: TEKLA HEALTHCARE INVESTORS - Form N-PX

Date of reporting period: **7/1/17-6/30/18**

Form N-PX is to be used by a registered management investment company, other than a small business investment company registered on Form N-5 (ss.ss.239.24 and 274.5 of this chapter), to file reports with the Commission, not later than August 31 of each year, containing the registrant's proxy voting record for the most recent twelve-month period ended June 30, pursuant to section 30 of the Investment Company Act of 1940 and rule 30b1-4 thereunder (17 CFR 270.30b1-4). The Commission may use the information provided on Form N-PX in its regulatory, disclosure review, inspection, and policymaking roles.

A registrant is required to disclose the information specified by Form N-PX, and the Commission will make this information public. A registrant is not required to respond to the collection of information contained in Form N-PX unless the Form displays a currently valid Office of Management and Budget (OMB) control number. Please direct comments concerning the accuracy of the information collection burden estimate and any suggestions for reducing the burden to the Secretary, Securities and Exchange Commission, 450 Fifth Street, NW, Washington, DC 20549-0609. The OMB has reviewed this collection of information under the clearance requirements of 44 U.S.C. ss. 3507.

---

**Item 1. Proxy Voting Record.**

---

*Vote Summary***ABBOTT LABORATORIES**

<b>Security</b>	002824100	<b>Meeting Type</b>	Annual
<b>Ticker Symbol</b>	ABT	<b>Meeting Date</b>	27-Apr-2018
<b>Record Date</b>	28-Feb-2018		

Item	Proposal	Proposed by	Vote	For/Against Management
1.	DIRECTOR	Management		
	1	R.J. Alpern	For	For
	2	R.S. Austin	For	For
	3	S.E. Blount	For	For
	4	E.M. Liddy	For	For
	5	N. McKinstry	For	For
	6	P.N. Novakovic	For	For
	7	W.A. Osborn	For	For
	8	S.C. Scott III	For	For
	9	D.J. Starks	For	For
	10	J.G. Stratton	For	For
	11	G.F. Tilton	For	For
	12	M.D. White	For	For
2.	Ratification of Ernst & Young LLP as Auditors	Management	For	For
3.	Say on Pay - An Advisory Vote to Approve Executive Compensation	Management	For	For
4.	Shareholder Proposal - Independent Board Chairman	Shareholder	For	Against

**ABBVIE INC.**

<b>Security</b>	00287Y109	<b>Meeting Type</b>	Annual
<b>Ticker Symbol</b>	ABBV	<b>Meeting Date</b>	04-May-2018
<b>Record Date</b>	07-Mar-2018		

Item	Proposal	Proposed by	Vote	For/Against Management
1.	DIRECTOR	Management		
	1	Roxanne S. Austin	For	For
	2	Richard A. Gonzalez	For	For
	3	Rebecca B. Roberts	For	For
	4	Glenn F. Tilton	For	For
2.	Ratification of Ernst & Young LLP as AbbVie's independent registered public accounting firm for 2018	Management	For	For
3.	Say on Pay - An advisory vote on the approval of executive compensation	Management	For	For
4.	Say When on Pay - An advisory vote on the frequency of the advisory vote to approve executive compensation	Management	1 Year	For
5.		Management	For	For

Edgar Filing: TEKLA HEALTHCARE INVESTORS - Form N-PX

	Approval of a management proposal regarding amendment of the certificate of incorporation for the annual election of directors			
6.	Approval of a management proposal regarding amendment of the certificate of incorporation to eliminate supermajority voting	Management	For	For
7.	Stockholder Proposal - to Issue an Annual Report on Lobbying	Shareholder	Against	For
8.	Stockholder Proposal - to Separate Chair and CEO	Shareholder	For	Against
9.	Stockholder Proposal - to Issue an Annual Compensation Committee Report on Drug Pricing	Shareholder	Against	For

---

## AC IMMUNE SA

<b>Security</b>	H00263105	<b>Meeting Type</b>	Special
<b>Ticker Symbol</b>	ACIU	<b>Meeting Date</b>	27-Apr-2018
<b>Record Date</b>	13-Mar-2018		

<b>Item</b>	<b>Proposal</b>	<b>Proposed by</b>	<b>Vote</b>	<b>For/Against Management</b>
1.	In the event that at the Extraordinary Shareholders Meeting, shareholders or the Board of Directors make additional or amended motions to the published agenda items and/or put forward new motions or in absence of any specific instruction, I/we instruct the independent proxy to vote in respect to such motions as proposed by the Board of Directors	Management	For	N/A
2.A	Election of Douglas Williams as Member to the Board of Directors	Management	For	N/A
2.B	Election of Douglas Williams to the Compensation, Nomination & Corporate Governance Committee	Management	For	N/A
3.a	Vote on Total Non-Performance-Related Compensation for the new Member of the Board of Directors from 27 April 2018 to 30 June 2018	Management	For	N/A
3.b	Vote on Equity for the new Member of the Board of Directors	Management	For	N/A
4.a	Share Capital Increase for Institutional Investors	Management	For	N/A
4.b	Share Capital Increase for Current Shareholders	Management	For	N/A

Edgar Filing: TEKLA HEALTHCARE INVESTORS - Form N-PX

AC IMMUNE SA

<b>Security Ticker Symbol Record Date</b>	H00263105 ACIU 23-May-2018	<b>Meeting Type Meeting Date</b>	Annual 06-Jul-2018
-------------------------------------------	----------------------------------	----------------------------------	-----------------------

Item	Proposal	Proposed by	Vote	For/Against Management
A.	In the event that at the Annual General Meeting, shareholders or the Board of Directors make additional or amended motions to the published agenda items and/or put forward new motions or in absence of any specific instruction, I/we instruct the independent proxy to vote in respect to such motions as proposed by the Board of Directors	Management	For	N/A
1.	Approval of the Annual Report, Annual Statutory Financial Statements and Financial Statements under IFRS of AC Immune SA for the year 2017	Management	For	N/A
2.	Appropriation of Loss	Management	For	N/A
3.	Discharge of the Members of the Board of Directors and the Executive Committee	Management	For	N/A
4a.	Vote on Total Non-Performance-Related Compensation for Members of the Board of Directors from 1 July 2018 to 30 June 2019	Management	For	N/A
4b.	Vote on Equity for Members of the Board of Directors	Management	For	N/A
4c.	Vote on Total Non-Performance-Related Compensation for Members of the Executive Committee from 1 July 2018 to 30 June 2019	Management	For	N/A
4d.	Vote on Total Variable Compensation for Members of the Executive Committee for the current year 2018	Management	For	N/A
4e.	Vote on Equity for Members of the Executive Committee	Management	For	N/A
5a.	Re-election of Martin Velasco as member and Chairman of the Board of Directors	Management	For	N/A
5b.	Re-election of Peter Bollmann as the Member of the Board	Management	For	N/A
5c.	Re-election of Friedrich von Bohlen as the Member of the Board	Management	For	N/A
5d.	Re-election of Andrea Pfeifer as the Member of the Board	Management	For	N/A
5e.	Re-election of Detlev Riesner as the Member of the Board including granting an exception to the age limit	Management	For	N/A
5f.	Re-election of Tom Graney as the Member of the Board	Management	For	N/A
5g.	Re-election of Douglas Williams as the Member of the Board	Management	For	N/A
5h.	Election of Werner Lanthaler as the Member of the Board	Management	For	N/A
6a.	Re-election of Tom Graney to the Compensation, Nomination & Corporate Governance Committee	Management	For	N/A
6b.	Re-election of Martin Velasco to the Compensation, Nomination & Corporate Governance Committee	Management	For	N/A
6c.	Re-election of Doug Williams to the Compensation, Nomination & Corporate Governance Committee	Management	For	N/A
7.	Re-election of the independent proxy Bugnion Ballansat Ehrler, represented by Gerald Virieux, avocat, Geneva	Management	For	N/A
8.	Election of the Auditors, PricewaterhouseCoopers SA, Pully	Management	For	N/A
9a.	Share Capital Increase for Institutional Investors	Management	For	N/A
9b.	Share Capital Increase for Current Shareholders	Management	For	N/A





Edgar Filing: TEKLA HEALTHCARE INVESTORS - Form N-PX

**ACADIA HEALTHCARE COMPANY, INC.**

<b>Security</b>	00404A109	<b>Meeting Type</b>	Annual
<b>Ticker Symbol</b>	ACHC	<b>Meeting Date</b>	03-May-2018
<b>Record Date</b>	09-Mar-2018		

Item	Proposal	Proposed by	Vote	For/Against Management
1.1	Election of Director: E. Perot Bissell	Management	For	For
1.2	Election of Director: Vicky B. Gregg	Management	For	For
2.	Advisory vote on the compensation of the Company's named executive officers as presented in the Proxy Statement.	Management	For	For
3.	Ratify the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2018.	Management	For	For

**ACADIA PHARMACEUTICALS INC.**

<b>Security</b>	004225108	<b>Meeting Type</b>	Annual
<b>Ticker Symbol</b>	ACAD	<b>Meeting Date</b>	06-Jun-2018
<b>Record Date</b>	13-Apr-2018		

Item	Proposal	Proposed by	Vote	For/Against Management
1.	DIRECTOR	Management		
	1 Julian Baker		For	For
	2 Stephen Biggar, M.D PhD		For	For
	3 Daniel Soland		For	For
2.	To approve an amendment to our 2010 Equity Incentive Plan, as amended, to, among other things, increase the aggregate number of shares of common stock authorized for issuance under the plan by 6,700,000 shares.	Management	For	For
3.	To approve, on an advisory basis, the compensation of our named executive officers, as disclosed in the proxy statement for the annual meeting.	Management	For	For
4.	To ratify the selection of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2018.	Management	For	For

**ACCELERON PHARMA INC.**

<b>Security</b>	00434H108	<b>Meeting Type</b>	Annual
<b>Ticker Symbol</b>	XLRN	<b>Meeting Date</b>	06-Jun-2018
<b>Record Date</b>	09-Apr-2018		

Edgar Filing: TEKLA HEALTHCARE INVESTORS - Form N-PX

<b>Item</b>	<b>Proposal</b>	<b>Proposed by</b>	<b>Vote</b>	<b>For/Against Management</b>
1a.	Election of Class II Director: Habib J. Dable	Management	For	For
1b.	Election of Class II Director: Terrence C. Kearney	Management	For	For
1c.	Election of Class II Director: Karen L. Smith, M.D., Ph.D.	Management	For	For
2.	To approve, on an advisory basis, the compensation paid to the Company's named executive officers as disclosed in the proxy statement.	Management	For	For
3.	To ratify the selection of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2018.	Management	For	For

---

Edgar Filing: TEKLA HEALTHCARE INVESTORS - Form N-PX

**AKEBIA THERAPEUTICS, INC.**

<b>Security</b>	00972D105	<b>Meeting Type</b>	Annual
<b>Ticker Symbol</b>	AKBA	<b>Meeting Date</b>	14-Jun-2018
<b>Record Date</b>	20-Apr-2018		

Item	Proposal	Proposed by	Vote	For/Against Management
1.	DIRECTOR	Management		
	1	Michael D. Clayman	For	For
	2	Duane Nash	For	For
	3	Ronald C. Renaud, Jr.	For	For
	4	John P. Butler	For	For
	5	Muneer A. Satter	For	For
	6	Michael S. Wyzga	For	For
2.	Ratification of the appointment of Ernst & Young LLP as the company's independent registered public accounting firm for the fiscal year ending December 31, 2018.	Management	For	For

**ALBIREO PHARMA INC.**

<b>Security</b>	01345P106	<b>Meeting Type</b>	Annual
<b>Ticker Symbol</b>	ALBO	<b>Meeting Date</b>	08-Jun-2018
<b>Record Date</b>	18-Apr-2018		

Item	Proposal	Proposed by	Vote	For/Against Management
1.	DIRECTOR	Management		
	1	Ronald H.W. Cooper	For	For
	2	Anne Klibanski, M.D.	For	For
	3	Stephanie S. Okey, M.S.	For	For
2.	To approve the Albireo Pharma, Inc. 2018 Equity Incentive Plan.	Management	For	For
3.	To approve the Albireo Pharma, Inc. 2018 Employee Stock Purchase Plan.	Management	For	For
4.	To ratify the appointment of Ernst & Young LLP as Albireo's independent registered public accounting firm for the fiscal year ending December 31, 2018.	Management	For	For

**ALDER BIOPHARMACEUTICALS, INC.**

<b>Security</b>	014339105	<b>Meeting Type</b>	Annual
<b>Ticker Symbol</b>	ALDR	<b>Meeting Date</b>	23-May-2018
<b>Record Date</b>	20-Apr-2018		

Item	Proposal	Proposed by	Vote	For/Against Management
------	----------	-------------	------	------------------------

Edgar Filing: TEKLA HEALTHCARE INVESTORS - Form N-PX

1.	DIRECTOR		Management		
	1	Paul B. Cleveland		For	For
	2	Stephen M. Dow		For	For
	3	A. Bruce Montgomery		For	For
2.	To approve, on an advisory basis, the compensation of the Company's named executive officers, as disclosed in the accompanying proxy statement.		Management	For	For
3.	To ratify the selection by the Audit Committee of the Board of Directors of PricewaterhouseCoopers LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2018.		Management	For	For

---

## ALEXION PHARMACEUTICALS, INC.

<b>Security</b>	015351109	<b>Meeting Type</b>	Annual
<b>Ticker Symbol</b>	ALXN	<b>Meeting Date</b>	08-May-2018
<b>Record Date</b>	12-Mar-2018		

Item	Proposal	Proposed by	Vote	For/Against Management
1.	DIRECTOR	Management		
	1	Felix J. Baker	For	For
	2	David R. Brennan	For	For
	3	Christopher J. Coughlin	For	For
	4	Deborah Dunsire	For	For
	5	Paul A. Friedman	For	For
	6	Ludwig N. Hantson	For	For
	7	John T. Mollen	For	For
	8	Francois Nader	For	For
	9	Judith A. Reinsdorf	For	For
	10	Andreas Rummelt	For	For
2.	Ratification of appointment by the Board of Directors of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm.	Management	For	For
3.	Approval of a non-binding advisory vote of the 2017 compensation paid to Alexion's named executive officers.	Management	For	For
4.	To request the Board to require an independent Chairman.	Shareholder	For	Against

## ALKERMES PLC

<b>Security</b>	G01767105	<b>Meeting Type</b>	Annual
<b>Ticker Symbol</b>	ALKS	<b>Meeting Date</b>	23-May-2018
<b>Record Date</b>	23-Mar-2018		

Item	Proposal	Proposed by	Vote	For/Against Management
1a.	Election of Director: Floyd E. Bloom, M.D.	Management	For	For
1b.	Election of Director: Nancy L. Snyderman, M.D.	Management	For	For
1c.	Election of Director: Nancy Wysenski	Management	For	For
2.	To approve, on an advisory basis, the compensation of the Company's named executive officers.	Management	For	For
3.	To hold a non-binding, advisory vote, on the frequency of future advisory votes on the compensation paid to the Company's named executive officers.	Management	1 Year	For
4.	To ratify, on a non-binding, advisory basis, the appointment of PricewaterhouseCoopers LLP as the independent auditor and accounting firm of the Company and to authorize, in a binding vote, the Audit and Risk Committee of the Board of Directors to set the independent auditor and accounting firm's remuneration.	Management	For	For
5.	To approve the Alkermes plc 2018 Stock Option and Incentive plan.	Management	For	For



Edgar Filing: TEKLA HEALTHCARE INVESTORS - Form N-PX

**ALLERGAN PLC**

<b>Security</b>	G0177J108	<b>Meeting Type</b>	Annual
<b>Ticker Symbol</b>	AGN	<b>Meeting Date</b>	02-May-2018
<b>Record Date</b>	06-Mar-2018		

Item	Proposal	Proposed by	Vote	For/Against Management
1a.	Election of Director: Nesli Basgoz, M.D.	Management	For	For
1b.	Election of Director: Paul M. Bisaro	Management	For	For
1c.	Election of Director: Joseph H. Boccuzzi	Management	For	For
1d.	Election of Director: Christopher W. Bodine	Management	For	For
1e.	Election of Director: Adriane M. Brown	Management	For	For
1f.	Election of Director: Christopher J. Coughlin	Management	For	For
1g.	Election of Director: Carol Anthony (John) Davidson	Management	For	For
1h.	Election of Director: Catherine M. Klema	Management	For	For
1i.	Election of Director: Peter J. McDonnell, M.D.	Management	For	For
1j.	Election of Director: Patrick J. O. Sullivan	Management	For	For
1k.	Election of Director: Brenton L. Saunders	Management	For	For
1l.	Election of Director: Fred G. Weiss	Management	For	For
2.	To approve, in a non-binding vote, Named Executive Officer compensation.	Management	For	For
3.	To ratify, in a non-binding vote, the appointment of PricewaterhouseCoopers LLP as the Company's independent auditor for the fiscal year ending December 31, 2018 and to authorize, in a binding vote, the Board of Directors, acting through its Audit and Compliance Committee, to determine PricewaterhouseCoopers LLP's remuneration.	Management	For	For
4.	To renew the authority of the directors of the Company (the Directors) to issue shares.	Management	For	For
5A.	To renew the authority of the Directors to issue shares for cash without first offering shares to existing shareholders.	Management	For	For
5B.	To authorize the Directors to allot new shares up to an additional 5% for cash in connection with an acquisition or other capital investment.	Management	For	For
6.	To consider a shareholder proposal requiring an independent Board Chairman, if properly presented at the meeting.	Shareholder	Against	For

**ALLIQUA BIOMEDICAL, INC.**

<b>Security</b>	019621200	<b>Meeting Type</b>	Special
<b>Ticker Symbol</b>	ALQA	<b>Meeting Date</b>	13-Sep-2017
<b>Record Date</b>	26-Jul-2017		

Item	Proposal	Proposed by	Vote	For/Against Management
1.	TO RATIFY THE FILING AND EFFECTIVENESS OF THE CERTIFICATE OF AMENDMENT TO OUR AMENDED AND RESTATED CERTIFICATE OF	Management	For	For

INCORPORATION FILED WITH THE SECRETARY OF STATE OF THE STATE OF DELAWARE ON MAY 6, 2016 AND THE INCREASE IN THE NUMBER OF SHARES OF AUTHORIZED COMMON STOCK EFFECTED THEREBY.

- |    |                                                                                                                                                                                                                                                                                                                                                                                |            |     |     |
|----|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|-----|
| 2. | TO APPROVE THE PROPOSAL TO AUTHORIZE THE COMPANY S BOARD OF DIRECTORS, IN ITS DISCRETION BUT PRIOR TO THE ANNUAL MEETING OF THE COMPANY S STOCKHOLDERS IN 2018, TO AMEND THE COMPANY S CERTIFICATE OF INCORPORATION TO EFFECT A REVERSE STOCK SPLIT OF THE COMPANY S COMMON STOCK, AT A RATIO IN THE RANGE OF ...(DUE TO SPACE LIMITS, SEE PROXY STATEMENT FOR FULL PROPOSAL). | Management | For | For |
| 3. | TO APPROVE AN ADJOURNMENT OF THE SPECIAL MEETING, IF NECESSARY, TO SOLICIT ADDITIONAL PROXIES IF THERE ARE NOT SUFFICIENT VOTES IN FAVOR OF ANY OF THE FOREGOING PROPOSALS.                                                                                                                                                                                                    | Management | For | For |



**ALLIQUA BIOMEDICAL, INC.**

<b>Security</b>	019621309	<b>Meeting Type</b>	Special
<b>Ticker Symbol</b>	ALQA	<b>Meeting Date</b>	27-Apr-2018
<b>Record Date</b>	23-Mar-2018		

<b>Item</b>	<b>Proposal</b>	<b>Proposed by</b>	<b>Vote</b>	<b>For/Against Management</b>
1.	A proposal to approve the Asset Purchase Agreement, the Asset Sale Transaction and the other transactions contemplated by the Asset Purchase Agreement ( the Asset Sale Proposal ).	Management	For	For
2.	A proposal to approve, on an advisory, non-binding basis, certain compensation that has, will or may be paid or become payable to the Company s named executive officers in connection with the asset sale ( the Advisory Proposal ).	Management	For	For
3.	A proposal to adjourn or postpone the Special Meeting of stockholders, if necessary or appropriate, for the purpose of soliciting additional votes for the approval of the Asset Sale Proposal ( the Adjournment Proposal ).	Management	For	For

**ALLIQUA BIOMEDICAL, INC.**

<b>Security</b>	019621309	<b>Meeting Type</b>	Annual
<b>Ticker Symbol</b>	ALQA	<b>Meeting Date</b>	26-Jun-2018
<b>Record Date</b>	03-May-2018		

<b>Item</b>	<b>Proposal</b>	<b>Proposed by</b>	<b>Vote</b>	<b>For/Against Management</b>
1.	<b>DIRECTOR</b>	<b>Management</b>		
	1 David Johnson		For	For
	2 Joseph Leone		For	For
	3 Gary Restani		For	For
	4 Jeffrey Sklar		For	For
	5 Mark Wagner		For	For
2.	Ratification of the appointment of Marcum LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2018.	Management	For	For

**ALNYLAM PHARMACEUTICALS, INC.**

<b>Security</b>	02043Q107	<b>Meeting Type</b>	Annual
<b>Ticker Symbol</b>	ALNY	<b>Meeting Date</b>	10-May-2018
<b>Record Date</b>	15-Mar-2018		

Edgar Filing: TEKLA HEALTHCARE INVESTORS - Form N-PX

<b>Item</b>	<b>Proposal</b>	<b>Proposed by</b>	<b>Vote</b>	<b>For/Against Management</b>
1a.	Election of Class II Director: Dennis A. Ausiello, M.D.	Management	For	For
1b.	Election of Class II Director: John K. Clarke	Management	For	For
1c.	Election of Class II Director: Marsha H. Fanucci	Management	For	For
1d.	Election of Class II Director: David E.I. Pyott	Management	For	For
2.	To approve the 2018 Stock Incentive Plan.	Management	For	For
3.	To approve, in a non-binding advisory vote, the compensation of Alnylam's named executive officers.	Management	For	For
4.	To ratify the appointment of PricewaterhouseCoopers LLP, an independent registered public accounting firm, as Alnylam's independent auditors for the fiscal year ending December 31, 2018.	Management	For	For

## AMARIN CORPORATION PLC

<b>Security</b>	02311206	<b>Meeting Type</b>	Annual
<b>Ticker Symbol</b>	AMRN	<b>Meeting Date</b>	14-May-2018
<b>Record Date</b>	18-Apr-2018		

Item	Proposal	Proposed by	Vote	For/Against Management
1.	To re-elect Mr. John F. Thero as a director.	Management	For	For
2.	To re-elect Mr. Patrick J. O. Sullivan as a director.	Management	For	For
3.	To hold an advisory (non-binding) vote to approve the compensation of the Company's named executive officers as described in full in the accompanying Proxy Statement.	Management	For	For
4.	To appoint Ernst & Young LLP as auditors of the Company to hold office until the conclusion of the next general meeting at which accounts are laid before the Company and to authorize the Audit Committee of the Board of Directors of the Company to fix the auditors remuneration as described in the accompanying Proxy Statement.	Management	For	For

## AMGEN INC.

<b>Security</b>	031162100	<b>Meeting Type</b>	Annual
<b>Ticker Symbol</b>	AMGN	<b>Meeting Date</b>	22-May-2018
<b>Record Date</b>	23-Mar-2018		

Item	Proposal	Proposed by	Vote	For/Against Management
1a.	Election of Director: Dr. Wanda M. Austin	Management	For	For
1b.	Election of Director: Mr. Robert A. Bradway	Management	For	For
1c.	Election of Director: Dr. Brian J. Druker	Management	For	For
1d.	Election of Director: Mr. Robert A. Eckert	Management	For	For
1e.	Election of Director: Mr. Greg C. Garland	Management	For	For
1f.	Election of Director: Mr. Fred Hassan	Management	For	For
1g.	Election of Director: Dr. Rebecca M. Henderson	Management	For	For
1h.	Election of Director: Mr. Frank C. Herringer	Management	For	For
1i.	Election of Director: Mr. Charles M. Holley, Jr.	Management	For	For
1j.	Election of Director: Dr. Tyler Jacks	Management	For	For
1k.	Election of Director: Ms. Ellen J. Kullman	Management	For	For
1l.	Election of Director: Dr. Ronald D. Sugar	Management	For	For
1m.	Election of Director: Dr. R. Sanders Williams	Management	For	For
2.	Advisory vote to approve our executive compensation.	Management	For	For
3.	To ratify the selection of Ernst & Young LLP as our independent registered public accountants for the fiscal year ending December 31, 2018.	Management	For	For
4.	Stockholder proposal for an annual report on the extent to which risks related to public concern over drug pricing strategies are integrated into our executive incentive compensation.	Shareholder	Against	For

Edgar Filing: TEKLA HEALTHCARE INVESTORS - Form N-PX

AMICUS THERAPEUTICS, INC.

<b>Security</b>	03152W109	<b>Meeting Type</b>	Annual
<b>Ticker Symbol</b>	FOLD	<b>Meeting Date</b>	07-Jun-2018
<b>Record Date</b>	16-Apr-2018		

Item	Proposal	Proposed by	Vote	For/Against Management
1.	DIRECTOR	Management		
	1 Donald J. Hayden, Jr.		For	For
	2 Craig Wheeler		For	For
2.	Proposal to approve an amendment to our Restated Certificate of Incorporation to increase the number of shares of common stock, par value \$0.01 per share, that we are authorized to issue from 250,000,000 to 500,000,000	Management	For	For
3.	Approval of the Amended and Restated 2007 Equity Incentive Plan to add 5,000,000 shares to the equity pool	Management	For	For
4.	Ratify the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2018	Management	For	For
5.	Approval, on an advisory basis, the Company's executive compensation	Management	For	For

---

Edgar Filing: TEKLA HEALTHCARE INVESTORS - Form N-PX

**AMPHIVENA THERAPEUTICS, INC**

<b>Security</b>	N/A	<b>Meeting Type</b>	Written Consent
<b>Ticker Symbol</b>	N/A	<b>Meeting Date</b>	20-Dec-2017
<b>Record Date</b>	N/A		

<b>Item</b>	<b>Proposal</b>	<b>Proposed by</b>	<b>Vote</b>	<b>For/Against Management</b>
1.	Approval of Amended and Restated Certificate of Incorporation	Management	For	For
2.	Approval of Bridge Loan and Waiver of Right of First Offer	Management	For	For
3.	Omnibus Resolutions	Management	For	For

**ANTHEM, INC.**

<b>Security</b>	036752103	<b>Meeting Type</b>	Annual
<b>Ticker Symbol</b>	ANTM	<b>Meeting Date</b>	16-May-2018
<b>Record Date</b>	09-Mar-2018		

<b>Item</b>	<b>Proposal</b>	<b>Proposed by</b>	<b>Vote</b>	<b>For/Against Management</b>
1a.	Election of Director: Lewis Hay, III	Management	For	For
1b.	Election of Director: Julie A. Hill	Management	For	For
1c.	Election of Director: Antonio F. Neri	Management	For	For
1d.	Election of Director: Ramiro G. Peru	Management	For	For
2.	To ratify the appointment of Ernst & Young LLP as the independent registered public accounting firm for 2018.	Management	For	For
3.	Advisory vote to approve the compensation of our named executive officers.	Management	For	For
4.	To approve proposed amendments to our Articles of Incorporation to allow shareholders owning 20% or more of our common stock to call special meetings of shareholders.	Management	For	For
5.	Shareholder proposal to allow shareholders owning 10% or more of our common stock to call special meetings of shareholders.	Shareholder	Against	For

**ARENA PHARMACEUTICALS, INC.**

<b>Security</b>	040047607	<b>Meeting Type</b>	Annual
<b>Ticker Symbol</b>	ARNA	<b>Meeting Date</b>	13-Jun-2018
<b>Record Date</b>	24-Apr-2018		

<b>Item</b>	<b>Proposal</b>	<b>Proposed by</b>	<b>Vote</b>	<b>For/Against Management</b>
-------------	-----------------	--------------------	-------------	-------------------------------

Edgar Filing: TEKLA HEALTHCARE INVESTORS - Form N-PX

1.	DIRECTOR		Management		
	1	Jayson Dallas, M.D.		For	For
	2	Oliver Fetzer, Ph.D.		For	For
	3	Jennifer Jarrett		For	For
	4	Amit D. Munshi		For	For
	5	Garry A. Neil, M.D.		For	For
	6	Tina S. Nova, Ph.D.		For	For
	7	Randall E. Woods		For	For
2.	To approve, on an advisory basis, the compensation of our named executive officers, as disclosed in the proxy statement accompanying this notice.		Management	For	For
3.	To approve the amendment and restatement of the Arena Pharmaceuticals, Inc., 2017 Long-Term Incentive Plan to, among other things, increase the number of shares authorized for issuance under the 2017 Long-Term Incentive Plan.		Management	For	For
4.	To ratify the appointment of KPMG LLP, an independent registered public accounting firm, as our independent auditors for the fiscal year ending December 31, 2018.		Management	For	For

## ASCENDIS PHARMA A S

<b>Security</b>	04351P101	<b>Meeting Type</b>	Annual
<b>Ticker Symbol</b>	ASND	<b>Meeting Date</b>	29-May-2018
<b>Record Date</b>	19-Apr-2018		

<b>Item</b>	<b>Proposal</b>	<b>Proposed by</b>	<b>Vote</b>	<b>For/Against Management</b>
1.	Election of Chairman of the Meeting	Management	For	For
2.	Report on the Company's Activities during the Past Year	Management	For	For
3.	Presentation of Audited Annual Report with Auditor's Statement for Approval and Discharge of the Board of Directors and Management	Management	For	For
4.	Resolution on Application of Profits or Covering of Losses as per the Adopted Annual Report	Management	For	For
5a.	Election of Board Member: Albert Cha (Class II)	Management	For	For
5b.	Election of Board Member: Birgitte Volck (Class II)	Management	For	For
5c.	Election of Board Member: Martin Olin (Class II)	Management	For	For
6.	Election of State-authorized Public Auditor	Management	For	For
7.	Any proposals from the Board of Directors and/or Shareholders: The Board of Directors proposes to renew the authorisation to the Board of Directors to issue warrants. Please refer to the Notice for additional information.	Management	For	For

## AURIS MEDICAL HOLDING AG

<b>Security</b>	H03579101	<b>Meeting Type</b>	Annual
<b>Ticker Symbol</b>	EARS	<b>Meeting Date</b>	12-Mar-2018
<b>Record Date</b>	09-Feb-2018		

Item	Proposal	Proposed by	Vote	For/Against Management
1.	Approval of the merger between Auris Medical Holding AG (as transferring entity) and Auris Medical NewCo Holding AG (as surviving entity) according to the terms and conditions set forth by the merger agreement dated 9 February 2018 and based on the interim balance sheet of Auris Medical Holding AG as of 30 September 2017. German Version: Genehmigung der Fusion zwischen der Auris Medical Holding AG (als ubertragende Gesellschaft) und der Auris ... (due to space limits, see proxy statement for full proposal).	Management	For	For
2.	Discharge of liability for the members of the Board of Directors and the Persons entrusted with the Company's Management. German Version: Entlastung der Mitglieder des Verwaltungsrats und der mit der Geschäftsführung der Gesellschaft betrauten Personen.	Management	For	For
3.1	Approval of the Compensation of the Board of Directors. German Version: Genehmigung der Vergütung des Verwaltungsrats.	Management	For	For
3.2	Approval of the Compensation of the members of the Executive Management Committee for the 2019 financial year. German Version: Genehmigung der Vergütung der Geschäftsleitung für das Geschäftsjahr 2019.	Management	For	For
4.1	Re-election of Thomas Meyer as member and as Chairman of the Board of Directors. German Version: Wiederwahl von Thomas Meyer als Mitglied und als Präsident des Verwaltungsrats.	Management	For	For
4.2	Re-election of Armando Anido as member of the Board of Directors. German Version: Wiederwahl von Armando Anido als Mitglied des Verwaltungsrats.	Management	For	For
4.3	Re-election of Mats Peter Blom as member of the Board of Directors. German Version: Wiederwahl von Mats Peter Blom als Mitglied des Verwaltungsrats.	Management	For	For
4.4	Re-election of Calvin W. Roberts as member of the Board of Directors. German Version: Wiederwahl von Calvin W. Roberts als Mitglied des Verwaltungsrats.	Management	For	For
4.5	Election of Alain Munoz as member of the Board of Directors. German Version: Wahl von Alain Munoz als Mitglied des Verwaltungsrats.	Management	For	For
5.1	Re-election of Armando Anido as member of the Compensation Committee. German Version: Wiederwahl von Armando Anido als Mitglied des Vergütungsausschusses.	Management	For	For
5.2	Election of Alain Munoz as member of the Compensation Committee. German Version: Wahl von Alain Munoz als Mitglied des Vergütungsausschusses.	Management	For	For
6.	Re-election of Deloitte AG as Auditors. German Version: Wiederwahl von Deloitte AG als Revisionsstelle.	Management	For	For



Edgar Filing: TEKLA HEALTHCARE INVESTORS - Form N-PX

7.	Re-election of the Independent Proxy. German Version: Wiederwahl des unabhängigen Stimmrechtsvertreters.	Management	For	For
8.	General instruction on new proposals of the Board of Directors. German Version: Allgemeine Weisungen zu nicht angekündigten Anträgen / Verhandlungsgegenständen.	Management	For	For

---

**BEIGENE LTD**

<b>Security</b>	07725L102	<b>Meeting Type</b>	Annual
<b>Ticker Symbol</b>	BGNE	<b>Meeting Date</b>	06-Jun-2018
<b>Record Date</b>	20-Apr-2018		

<b>Item</b>	<b>Proposal</b>	<b>Proposed by</b>	<b>Vote</b>	<b>For/Against Management</b>
1.	THAT Donald W. Glazer be and is hereby re-elected to serve as a Class II director of the Company until the 2021 annual general ... (due to space limits, see proxy material for full proposal).	Management	For	For
2.	THAT Michael Goller be and is hereby re-elected to serve as a ... (due to space limits, see proxy material for full proposal).	Management	For	For
3.	THAT Thomas Malley be and is hereby re-elected to serve as a Class II director of the Company until the 2021 annual general meeting of the shareholders of the Company and until his successor is duly elected and qualified, subject to his earlier resignation or removal.	Management	For	For
4.	THAT the BeiGene, Ltd. 2018 Employee Share Purchase Plan be and is hereby approved and adopted.	Management	For	For
5.	THAT the appointment of Ernst & Young Hua Ming LLP as the Company's independent registered public accounting firm for the ... (due to space limits, see proxy material for full proposal).	Management	For	For
6.	THAT, on a non-binding, advisory basis, the compensation of the Company's named executive officers, as disclosed in the Proxy Statement for the Meeting, be and is hereby approved.	Management	For	For
7.	THAT, on a non-binding, advisory basis, future advisory votes on the compensation of the Company's named executive officers will be held at the frequency hereby approved.	Management	1 Year	For

**BIOCLIN THERAPEUTICS, INC.**

<b>Security</b>	N/A	<b>Meeting Type</b>	Written Consent
<b>Ticker Symbol</b>	N/A	<b>Meeting Date</b>	27-Sep-2017
<b>Record Date</b>	N/A		

<b>Item</b>	<b>Proposal</b>	<b>Proposed by</b>	<b>Vote</b>	<b>For/Against Management</b>
1.	Election of Director	Management	For	For
2.	General Authorizing Resolution	Management	For	For

**BIOCLIN THERAPEUTICS, INC.**

Edgar Filing: TEKLA HEALTHCARE INVESTORS - Form N-PX

<b>Security</b>	N/A	<b>Meeting Type</b>	Written Consent
<b>Ticker Symbol</b>	N/A	<b>Meeting Date</b>	24-Apr-2018
<b>Record Date</b>	N/A		

<b>Item</b>	<b>Proposal</b>	<b>Proposed by</b>	<b>Vote</b>	<b>For/Against Management</b>
1.	Amendment and Restatement of Restated Certificate of Incorporation	Management	For	For
2.	Series B Preferred Stock Financing	Management	For	For
3.	Waiver of Preemptive Rights	Management	For	For
4.	Notice of Interested Party Transactions	Management	For	For
5.	Amendment of 2013 Stock and Option Grant Plan	Management	For	For
6.	General Authorizing Resolution	Management	For	For

---

**BIOCLIN THERAPEUTICS, INC.**

<b>Security</b>	N/A	<b>Meeting Type</b>	Written Consent
<b>Ticker Symbol</b>	N/A	<b>Meeting Date</b>	21-May-2018
<b>Record Date</b>	N/A		

<b>Item</b>	<b>Proposal</b>	<b>Proposed by</b>	<b>Vote</b>	<b>For/Against Management</b>
1.	Election of Director	Management	For	For
2.	General Authorizing Resolution	Management	For	For

**BIOGEN INC.**

<b>Security</b>	09062X103	<b>Meeting Type</b>	Annual
<b>Ticker Symbol</b>	BIIB	<b>Meeting Date</b>	12-Jun-2018
<b>Record Date</b>	17-Apr-2018		

<b>Item</b>	<b>Proposal</b>	<b>Proposed by</b>	<b>Vote</b>	<b>For/Against Management</b>
1a.	Election of Director: Alexander J. Denner	Management	For	For
1b.	Election of Director: Caroline D. Dorsa	Management	For	For
1c.	Election of Director: Nancy L. Leaming	Management	For	For
1d.	Election of Director: Richard C. Mulligan	Management	For	For
1e.	Election of Director: Robert W. Pangia	Management	For	For
1f.	Election of Director: Stelios Papadopoulos	Management	For	For
1g.	Election of Director: Brian S. Posner	Management	For	For
1h.	Election of Director: Eric K. Rowinsky	Management	For	For
1i.	Election of Director: Lynn Schenk	Management	For	For
1j.	Election of Director: Stephen A. Sherwin	Management	For	For
1k.	Election of Director: Michel Vounatsos	Management	For	For
2.	To ratify the selection of PricewaterhouseCoopers LLP as Biogen Inc. s independent registered public accounting firm for the fiscal year ending December 31, 2018.	Management	For	For
3.	Say on Pay - To approve an advisory vote on executive compensation.	Management	For	For
4.	Stockholder proposal requesting certain proxy access bylaw amendments.	Shareholder	Against	For
5.	Stockholder proposal requesting a report on the extent to which risks related to public concern over drug pricing strategies are integrated into incentive compensation arrangements.	Shareholder	Against	For

**BIOHAVEN PHARMACEUTICAL HLDG CO LTD**

<b>Security</b>	G11196105	<b>Meeting Type</b>	Annual
<b>Ticker Symbol</b>	BHVN	<b>Meeting Date</b>	01-May-2018
<b>Record Date</b>	26-Mar-2018		

<b>Item</b>	<b>Proposal</b>	<b>Proposed by</b>	<b>Vote</b>	<b>For/Against Management</b>
1A.	Election of Director: Dr. Eric I. Aguiar	Management	For	For
1B.	Election of Director: Dr. Albert Cha	Management	For	For
1C.	Election of Director: Ms. Julia P. Gregory	Management	For	For
2.	Ratification of appointment of PricewaterhouseCoopers LLP as independent auditors for fiscal year 2018.	Management	For	For

**BIOMARIN PHARMACEUTICAL INC.**

<b>Security</b>	09061G101	<b>Meeting Type</b>	Annual
<b>Ticker Symbol</b>	BMRN	<b>Meeting Date</b>	05-Jun-2018
<b>Record Date</b>	09-Apr-2018		

<b>Item</b>	<b>Proposal</b>	<b>Proposed by</b>	<b>Vote</b>	<b>For/Against Management</b>
1.	<b>DIRECTOR</b>	<b>Management</b>		
	1 Jean-Jacques Bienaime		For	For
	2 Willard Dere		For	For
	3 Michael Grey		For	For
	4 Elaine J. Heron		For	For
	5 Robert J. Hombach		For	For
	6 V. Bryan Lawlis		For	For
	7 Alan J. Lewis		For	For
	8 Richard A. Meier		For	For
	9 David E.I. Pyott		For	For
	10 Dennis J. Slamon		For	For
2.	To ratify the selection of KPMG LLP as the independent registered public accounting firm for BioMarin for the fiscal year ending December 31, 2018.	Management	For	For
3.	To approve, on an advisory basis, the compensation of the Company's Named Executive Officers as disclosed in the Proxy Statement.	Management	For	For

**BLUEBIRD BIO, INC.**

<b>Security</b>	09609G100	<b>Meeting Type</b>	Annual
<b>Ticker Symbol</b>	BLUE	<b>Meeting Date</b>	20-Jun-2018
<b>Record Date</b>	23-Apr-2018		

Edgar Filing: TEKLA HEALTHCARE INVESTORS - Form N-PX

<b>Item</b>	<b>Proposal</b>	<b>Proposed by</b>	<b>Vote</b>	<b>For/Against Management</b>
1a.	Election of Class II Director: John O. Agwunobi, M.D.	Management	For	For
1b.	Election of Class II Director: Mary Lynne Hedley, Ph.D	Management	For	For
1c.	Election of Class II Director: Daniel S. Lynch	Management	For	For
2.	To hold a non-binding advisory vote on the compensation paid to the Company's named executive officers.	Management	For	For
3.	To ratify the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2018.	Management	For	For

---

**BLUEPRINT MEDICINES CORPORATION**

<b>Security</b>	09627Y109	<b>Meeting Type</b>	Annual
<b>Ticker Symbol</b>	BPMC	<b>Meeting Date</b>	20-Jun-2018
<b>Record Date</b>	23-Apr-2018		

Item	Proposal	Proposed by	Vote	For/Against Management
1.	DIRECTOR	Management		
	1 Daniel S. Lynch		For	For
	2 George D. Demetri, M.D.		For	For
	3 Lynn Seely, M.D.		For	For
2.	To approve an advisory vote on named executive officer compensation.	Management	For	For
3.	To hold an advisory vote on the frequency of future advisory votes on named executive officer compensation.	Management	1 Year	For
4.	Ratification of the appointment of Ernst & Young LLP as independent registered public accounting firm for the fiscal year ended December 31, 2018.	Management	For	For

**BRISTOL-MYERS SQUIBB COMPANY**

<b>Security</b>	110122108	<b>Meeting Type</b>	Annual
<b>Ticker Symbol</b>	BMY	<b>Meeting Date</b>	01-May-2018
<b>Record Date</b>	14-Mar-2018		

Item	Proposal	Proposed by	Vote	For/Against Management
1A.	Election of Director: P. J. Arduini	Management	For	For
1B.	Election of Director: J. Baselga, M.D., Ph.D.	Management	For	For
1C.	Election of Director: R. J. Bertolini	Management	For	For
1D.	Election of Director: G. Caforio, M.D.	Management	For	For
1E.	Election of Director: M. W. Emmens	Management	For	For
1F.	Election of Director: M. Grobstein	Management	For	For
1G.	Election of Director: A. J. Lacy	Management	For	For
1H.	Election of Director: D. C. Paliwal	Management	For	For
1I.	Election of Director: T. R. Samuels	Management	For	For
1J.	Election of Director: G. L. Storch	Management	For	For
1K.	Election of Director: V. L. Sato, Ph.D.	Management	For	For
1L.	Election of Director: K. H. Vousden, Ph.D.	Management	For	For
2.	Advisory vote to approve the compensation of our Named Executive Officers	Management	For	For
3.	Ratification of the appointment of an independent registered public accounting firm	Management	For	For
4.	Shareholder Proposal on Annual Report Disclosing How Risks Related to Public Concern Over Drug Pricing Strategies are Incorporated into Incentive Compensation Plans	Shareholder	Against	For
5.	Shareholder Proposal to Lower the Share Ownership Threshold to Call Special Shareholder Meetings	Shareholder	Against	For





## CARDINAL HEALTH, INC.

<b>Security</b>	14149Y108	<b>Meeting Type</b>	Annual
<b>Ticker Symbol</b>	CAH	<b>Meeting Date</b>	08-Nov-2017
<b>Record Date</b>	11-Sep-2017		

<b>Item</b>	<b>Proposal</b>	<b>Proposed by</b>	<b>Vote</b>	<b>For/Against Management</b>
1A.	ELECTION OF DIRECTOR: DAVID J. ANDERSON	Management	For	For
1B.	ELECTION OF DIRECTOR: COLLEEN F. ARNOLD	Management	For	For
1C.	ELECTION OF DIRECTOR: GEORGE S. BARRETT	Management	For	For
1D.	ELECTION OF DIRECTOR: CARRIE S. COX	Management	For	For
1E.	ELECTION OF DIRECTOR: CALVIN DARDEN	Management	For	For
1F.	ELECTION OF DIRECTOR: BRUCE L. DOWNEY	Management	For	For
1G.	ELECTION OF DIRECTOR: PATRICIA A. HEMINGWAY HALL	Management	For	For
1H.	ELECTION OF DIRECTOR: CLAYTON M. JONES	Management	For	For
1I.	ELECTION OF DIRECTOR: GREGORY B. KENNY	Management	For	For
1J.	ELECTION OF DIRECTOR: NANCY KILLEFER	Management	For	For
1K.	ELECTION OF DIRECTOR: DAVID P. KING	Management	For	For
2.	PROPOSAL TO RATIFY THE APPOINTMENT OF ERNST & YOUNG LLP AS OUR INDEPENDENT AUDITOR FOR THE FISCAL YEAR ENDING JUNE 30, 2018.	Management	For	For
3.	PROPOSAL TO APPROVE, ON A NON-BINDING ADVISORY BASIS, THE COMPENSATION OF OUR NAMED EXECUTIVE OFFICERS.	Management	For	For
4.	PROPOSAL TO VOTE, ON A NON-BINDING ADVISORY BASIS, ON THE FREQUENCY OF FUTURE ADVISORY VOTES TO APPROVE EXECUTIVE COMPENSATION.	Management	1 Year	For
5.	SHAREHOLDER PROPOSAL, IF PROPERLY PRESENTED, TO URGE THE BOARD OF DIRECTORS TO ADOPT A POLICY THAT THE CHAIRMAN OF THE BOARD BE AN INDEPENDENT DIRECTOR.	Shareholder	Against	For
6.	SHAREHOLDER PROPOSAL, IF PROPERLY PRESENTED, TO REQUEST THAT THE BOARD OF DIRECTORS ADOPT A BYLAW PROVISION RESTRICTING MANAGEMENT'S ACCESS TO VOTE TALLIES PRIOR TO THE ANNUAL MEETING WITH RESPECT TO CERTAIN EXECUTIVE PAY MATTERS.	Shareholder	Against	For

Edgar Filing: TEKLA HEALTHCARE INVESTORS - Form N-PX

**CELGENE CORPORATION**

<b>Security</b>	151020104	<b>Meeting Type</b>	Annual
<b>Ticker Symbol</b>	CELG	<b>Meeting Date</b>	13-Jun-2018
<b>Record Date</b>	19-Apr-2018		

Item	Proposal	Proposed by	Vote	For/Against Management
1.	DIRECTOR	Management		
	1 Mark J. Alles		For	For
	2 R W Barker, D.Phil, OBE		For	For
	3 Hans E. Bishop		For	For
	4 Michael W. Bonney		For	For
	5 Michael D. Casey		For	For
	6 Carrie S. Cox		For	For
	7 Michael A. Friedman, MD		For	For
	8 Julia A. Haller, M.D.		For	For
	9 P. A. Hemingway Hall		For	For
	10 James J. Loughlin		For	For
	11 Ernest Mario, Ph.D.		For	For
	12 John H. Weiland		For	For
2.	Ratification of the appointment of KPMG LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2018.	Management	For	For
3.	Approval, by non-binding vote, of executive compensation of the Company's named executive officers.	Management	For	For
4.	Advisory vote on stockholder proposal to request the Company's Board of Directors to amend the Company's proxy access by-law provision to eliminate the limit on the number of stockholders that can aggregate their shares to achieve the holding requirement for nomination of directors, described in more detail in the proxy statement.	Shareholder	Against	For
5.	Advisory vote on stockholder proposal to request the Company's Board of Directors to adopt a policy and amend the Company's governing documents to require that the Chairman of the Board be an independent member, described in more detail in the proxy statement.	Shareholder	For	Against

**CENTENE CORPORATION**

<b>Security</b>	15135B101	<b>Meeting Type</b>	Annual
<b>Ticker Symbol</b>	CNC	<b>Meeting Date</b>	24-Apr-2018
<b>Record Date</b>	23-Feb-2018		

Item	Proposal	Proposed by	Vote	For/Against Management
1A.	Election of Director: Jessica L. Blume	Management	For	For
1B.	Election of Director: Frederick H. Eppinger	Management	For	For
1C.	Election of Director: David L. Steward	Management	For	For
2.		Management	For	For

Edgar Filing: TEKLA HEALTHCARE INVESTORS - Form N-PX

ADVISORY RESOLUTION TO APPROVE  
EXECUTIVE COMPENSATION.

3.	RATIFICATION OF APPOINTMENT OF KPMG LLP AS OUR INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE FISCAL YEAR ENDING DECEMBER 31, 2018.	Management	For	For
----	-----------------------------------------------------------------------------------------------------------------------------------------------------	------------	-----	-----

---

Edgar Filing: TEKLA HEALTHCARE INVESTORS - Form N-PX

**CLOVIS ONCOLOGY, INC.**

<b>Security</b>	189464100	<b>Meeting Type</b>	Annual
<b>Ticker Symbol</b>	CLVS	<b>Meeting Date</b>	07-Jun-2018
<b>Record Date</b>	09-Apr-2018		

<b>Item</b>	<b>Proposal</b>	<b>Proposed by</b>	<b>Vote</b>	<b>For/Against Management</b>
1.	DIRECTOR	Management		
	1 Patrick J. Mahaffy		For	For
	2 M. James Barrett, Ph.D.		For	For
	3 Thorlef Spickschen		For	For
2.	Approval and ratification of our Non-Employee Director Compensation Policy.	Management	For	For
3.	Approval of an advisory proposal on compensation of the Company's named executive officers, as disclosed in the attached proxy statement.	Management	For	For
4.	Approval of an advisory proposal on the preferred frequency of the stockholder vote on the compensation of the Company's named executive officers.	Management	1 Year	For
5.	Ratification of the appointment of Ernst & Young LLP as the independent registered public accounting firm of the Company for the fiscal year ending December 31, 2018.	Management	For	For

**COHERUS BIOSCIENCES INC**

<b>Security</b>	19249H103	<b>Meeting Type</b>	Annual
<b>Ticker Symbol</b>	CHRS	<b>Meeting Date</b>	23-May-2018
<b>Record Date</b>	02-Apr-2018		

<b>Item</b>	<b>Proposal</b>	<b>Proposed by</b>	<b>Vote</b>	<b>For/Against Management</b>
1.	DIRECTOR	Management		
	1 Christos Richards		For	For
	2 V. Bryan Lawlis, Ph.D.		For	For
2.	To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2018.	Management	For	For

## CRISPR THERAPEUTICS AG

<b>Security Ticker Symbol Record Date</b>	H17182108 CRSP 02-Apr-2018	<b>Meeting Type Meeting Date</b>	Annual 30-May-2018
-------------------------------------------	----------------------------------	----------------------------------	-----------------------

Item	Proposal	Proposed by	Vote	For/Against Management
1.	The approval of the annual report, the consolidated financial statements and the statutory financial statements of the Company for the year ended December 31, 2017.	Management	For	For
2.	The approval of the appropriation of financial results.	Management	For	For
3.	The discharge of the members of the Board of Directors and Executive Committee.	Management	For	For
4a.	Re-election of the member to the Board of Director: Rodger Novak, M.D. (as member and Chairman)	Management	For	For
4b.	Election of the member to the Board of Director: Samarth Kulkarni, Ph.D.	Management	For	For
4c.	Re-election of the member to the Board of Director: Bradley Bolzon, Ph.D.	Management	For	For
4d.	Re-election of the member to the Board of Director: Ali Behbahani, M.D.	Management	For	For
4e.	Re-election of the member to the Board of Director: Pablo Cagnoni, M.D.	Management	For	For
4f.	Re-election of the member to the Board of Director: Kurt von Emster	Management	For	For
4g.	Re-election of the member to the Board of Director: Simeon J. George, M.D.	Management	For	For
4h.	Re-election of the member to the Board of Director: Thomas Woiwode, Ph.D.	Management	For	For
5a.	Re-election of the member of the Compensation Committee: Thomas Woiwode, Ph.D.	Management	For	For
5b.	Re-election of the member of the Compensation Committee: Pablo Cagnoni, M.D.	Management	For	For
5c.	Re-election of the member of the Compensation Committee: Simeon J. George, M.D.	Management	For	For
6a.	Binding vote on total non-performance-related compensation for members of the Board of Directors from the 2018 Annual General Meeting to the 2019 annual general meeting of shareholders.	Management	For	For
6b.	Binding vote on equity for members of the Board of Directors from the 2018 Annual General Meeting to the 2019 annual general meeting of shareholders.	Management	For	For
6c.	Binding vote on total non-performance-related compensation for members of the Executive Committee from July 1, 2018 to June 30, 2019.	Management	For	For
6d.	Binding vote on total variable compensation for members of the Executive Committee for the current year ending December 31, 2018.	Management	For	For
6e.	Binding vote on equity for members of the Executive Committee from the 2018 Annual General Meeting to the 2019 annual general meeting of shareholders.	Management	For	For
7.	The approval of an increase in the Conditional Share Capital for Employee Benefit Plans.	Management	For	For
8.		Management	For	For

Edgar Filing: TEKLA HEALTHCARE INVESTORS - Form N-PX

	The approval of the CRISPR Therapeutics AG 2018 Stock Option and Incentive Plan.			
9.	The approval of increasing the maximum number of authorized share capital and extending the date by which the Board of Directors may increase authorized share capital.	Management	For	For
10.	The re-election of the independent voting rights representative.	Management	For	For
11.	The re-election of the auditors.	Management	For	For

---

**CYTOKINETICS, INCORPORATED**

<b>Security</b>	23282W605	<b>Meeting Type</b>	Annual
<b>Ticker Symbol</b>	CYTK	<b>Meeting Date</b>	16-May-2018
<b>Record Date</b>	03-Apr-2018		

Item	Proposal	Proposed by	Vote	For/Against Management
1.	DIRECTOR	Management		
	1 Robert I. Blum		For	For
	2 Robert M. Califf M.D.		For	For
	3 Sandford D. Smith		For	For
2.	Ratification of selection of Ernst & Young LLP as the independent registered public accounting firm of Cytokinetics, Incorporated for the fiscal year ending December 31, 2018.	Management	For	For
3.	Approval, on an advisory basis, of the compensation of the named executive officers.	Management	For	For

**CYTOX THERAPEUTICS, INC.**

<b>Security</b>	23284F105	<b>Meeting Type</b>	Annual
<b>Ticker Symbol</b>	CTMX	<b>Meeting Date</b>	13-Jun-2018
<b>Record Date</b>	23-Apr-2018		

Item	Proposal	Proposed by	Vote	For/Against Management
1a.	Election of Director: Charles S. Fuchs	Management	For	For
1b.	Election of Director: Hoyoung Huh	Management	For	For
2.	To ratify the selection of Ernst & Young LLP as our independent registered public accounting firm for our fiscal year ending December 31, 2018.	Management	For	For

**DERMIRA, INC.**

<b>Security</b>	24983L104	<b>Meeting Type</b>	Annual
<b>Ticker Symbol</b>	DERM	<b>Meeting Date</b>	12-Jun-2018
<b>Record Date</b>	16-Apr-2018		

Item	Proposal	Proposed by	Vote	For/Against Management
1.	DIRECTOR	Management		
	1 Matthew K. Fust		For	For
	2 William R. Ringo		For	For
	3 Kathleen Sebelius		For	For
2.	Vote, on a non-binding advisory basis, on the compensation paid by us to our named executive officers for the year ended December 31,	Management	For	For

Edgar Filing: TEKLA HEALTHCARE INVESTORS - Form N-PX

	2017.			
3.	Ratification of the appointment of Ernst & Young LLP as our independent registered public accounting firm for the year ending December 31, 2018.	Management	For	For
4.	Such other business as may properly come before the meeting or any adjournment thereof.	Management	Abstain	Against

---



## EDITAS MEDICINE INC

<b>Security</b>	28106W103	<b>Meeting Type</b>	Annual
<b>Ticker Symbol</b>	EDIT	<b>Meeting Date</b>	15-Jun-2018
<b>Record Date</b>	18-Apr-2018		

Item	Proposal	Proposed by	Vote	For/Against Management
1.	DIRECTOR	Management		
	1	Andrew Hirsch	For	For
	2	Boris Nikolic, M.D.	For	For
2.	Ratification of the selection of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2018.	Management	For	For

## EIGER BIOPHARMACEUTICALS,INC

<b>Security</b>	28249U105	<b>Meeting Type</b>	Annual
<b>Ticker Symbol</b>	EIGR	<b>Meeting Date</b>	12-Jun-2018
<b>Record Date</b>	23-Apr-2018		

Item	Proposal	Proposed by	Vote	For/Against Management
1.	DIRECTOR	Management		
	1	Thomas J. Dietz, Ph.D	For	For
	2	Eldon Mayer	For	For
2.	To ratify the selection by the Audit Committee of our Board of Directors of KPMG LLP as our independent registered public accounting firm for our fiscal year ending December 31, 2018.	Management	For	For

## ELI LILLY AND COMPANY

<b>Security</b>	532457108	<b>Meeting Type</b>	Annual
<b>Ticker Symbol</b>	LLY	<b>Meeting Date</b>	07-May-2018
<b>Record Date</b>	12-Mar-2018		

Item	Proposal	Proposed by	Vote	For/Against Management
1a.	Election of Director: K. Baicker	Management	For	For
1b.	Election of Director: J. E. Fyrwald	Management	For	For
1c.	Election of Director: J. Jackson	Management	For	For
1d.	Election of Director: E. R. Marram	Management	For	For
1e.	Election of Director: J. P. Tai	Management	For	For
2.	Approval, by non-binding vote, of the compensation paid to the company's named executive officers.	Management	For	For
3.		Management	For	For

Edgar Filing: TEKLA HEALTHCARE INVESTORS - Form N-PX

	Ratification of Ernst & Young LLP as the principal independent auditor for 2018.			
4.	Approve amendments to the Articles of Incorporation to eliminate the classified board structure.	Management	For	For
5.	Approve amendments to the Articles of Incorporation to eliminate supermajority voting provisions.	Management	For	For
6.	Approve the Amended and Restated 2002 Lilly Stock Plan.	Management	For	For
7.	Shareholder proposal seeking support for the descheduling of cannabis.	Shareholder	Against	For
8.	Shareholder proposal requesting report regarding direct and indirect political contributions.	Shareholder	Against	For
9.	Shareholder proposal requesting report on policies and practices regarding contract animal laboratories.	Shareholder	Against	For
10.	Shareholder proposal requesting report on extent to which risks related to public concern over drug pricing strategies are integrated into incentive compensation arrangements.	Shareholder	Against	For

---

## ENDO INTERNATIONAL PLC

<b>Security</b>	G30401106	<b>Meeting Type</b>	Annual
<b>Ticker Symbol</b>	ENDP	<b>Meeting Date</b>	07-Jun-2018
<b>Record Date</b>	13-Apr-2018		

Item	Proposal	Proposed by	Vote	For/Against Management
1a.	Election of Director: Roger H. Kimmel	Management	For	For
1b.	Election of Director: Paul V. Campanelli	Management	For	For
1c.	Election of Director: Shane M. Cooke	Management	For	For
1d.	Election of Director: Nancy J. Hutson, Ph.D.	Management	For	For
1e.	Election of Director: Michael Hyatt	Management	For	For
1f.	Election of Director: Sharad S. Mansukani, M.D.	Management	For	For
1g.	Election of Director: William P. Montague	Management	For	For
1h.	Election of Director: Todd B. Sisitsky	Management	For	For
2.	To approve the selection of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm for the year ending December 31, 2018 and to authorize the Board of Directors, acting through the Audit Committee, to determine the independent registered public accounting firm's remuneration.	Management	For	For
3.	To approve, by advisory vote, named executive officer compensation.	Management	For	For
4.	To approve the Endo International plc Amended and Restated 2015 Stock Incentive Plan.	Management	For	For
5.	To renew the Board's existing authority to issue shares under Irish law.	Management	For	For
6.	To renew the Board's existing authority to opt-out of statutory pre-emption rights under Irish law.	Management	For	For

## EPIZYME, INC.

<b>Security</b>	29428V104	<b>Meeting Type</b>	Annual
<b>Ticker Symbol</b>	EPZM	<b>Meeting Date</b>	18-May-2018
<b>Record Date</b>	23-Mar-2018		

Item	Proposal	Proposed by	Vote	For/Against Management
1.	DIRECTOR	Management		
	1 Kevin Conroy		For	For
	2 Carl Goldfischer, M.D.		For	For
	3 Beth Seidenberg, M.D.		For	For
2.	Ratification of the appointment of Ernst & Young LLP as Epizyme's independent registered public accounting firm for the fiscal year ending December 31, 2018.	Management	For	For

## ESPERION THERAPEUTICS INC

Edgar Filing: TEKLA HEALTHCARE INVESTORS - Form N-PX

<b>Security</b>	29664W105	<b>Meeting Type</b>	Annual
<b>Ticker Symbol</b>	ESPR	<b>Meeting Date</b>	23-May-2018
<b>Record Date</b>	26-Mar-2018		

<b>Item</b>	<b>Proposal</b>	<b>Proposed by</b>	<b>Vote</b>	<b>For/Against Management</b>
1a.	Election of Class II Director: Jeffrey Berkowitz, J.D.	Management	For	For
1b.	Election of Class II Director: Antonio M. Gotto Jr., M.D., D.Phil.	Management	For	For
1c.	Election of Class II Director: Nicole Vitullo	Management	For	For
2.	To approve the advisory resolution on the compensation of our named executive officers	Management	For	For
3.	To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2018	Management	For	For

**EUTHYMICS BIOSCIENCE, INC.**

<b>Security</b>	N/A	<b>Meeting Type</b>	Written Consent
<b>Ticker Symbol</b>	N/A	<b>Meeting Date</b>	11-Jul-2017
<b>Record Date</b>	N/A		

<b>Item</b>	<b>Proposal</b>	<b>Proposed by</b>	<b>Vote</b>	<b>For/Against Management</b>
1.	Bridge Financing	Management	For	For

**EUTHYMICS BIOSCIENCE, INC.**

<b>Security</b>	N/A	<b>Meeting Type</b>	Written Consent
<b>Ticker Symbol</b>	N/A	<b>Meeting Date</b>	27-Oct-2017
<b>Record Date</b>	N/A		

<b>Item</b>	<b>Proposal</b>	<b>Proposed by</b>	<b>Vote</b>	<b>For/Against Management</b>
1.	Sale and Dissolution	Management	For	For
2.	Dissolution	Management	For	For
3.	General	Management	For	For

**EVOLENT HEALTH, INC.**

<b>Security</b>	30050B101	<b>Meeting Type</b>	Annual
<b>Ticker Symbol</b>	EVH	<b>Meeting Date</b>	13-Jun-2018
<b>Record Date</b>	17-Apr-2018		

<b>Item</b>	<b>Proposal</b>	<b>Proposed by</b>	<b>Vote</b>	<b>For/Against Management</b>
1a.	Election of Class III Director: Bruce Felt	Management	For	For
1b.	Election of Class III Director: Kenneth Samet	Management	For	For
1c.	Election of Class III Director: Cheryl Scott	Management	For	For
1d.	Election of Class III Director: Frank Williams	Management	For	For
2.	Proposal to ratify the appointment of PricewaterhouseCoopers LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2018.	Management	For	For
3.	Proposal to approve an amendment of the Evolent Health, Inc. 2015 Omnibus Incentive Compensation Plan.	Management	For	For
4.	Proposal to approve the compensation of our named executive officers for 2017 on an advisory basis.	Management	For	For
5.	Proposal to approve the selection of the frequency of future advisory votes on executive compensation on an advisory basis.	Management	1 Year	For

**EXELIXIS, INC.**

<b>Security</b>	30161Q104	<b>Meeting Type</b>	Annual
<b>Ticker Symbol</b>	EXEL	<b>Meeting Date</b>	23-May-2018
<b>Record Date</b>	29-Mar-2018		

<b>Item</b>	<b>Proposal</b>	<b>Proposed by</b>	<b>Vote</b>	<b>For/Against Management</b>
1.1	Election of Class I Director: Charles Cohen, Ph.D.	Management	For	For
1.2		Management	For	For

## Edgar Filing: TEKLA HEALTHCARE INVESTORS - Form N-PX

Election of Class I Director: George Poste, DVM, Ph.D.,  
FRS

1.3	Election of Class I Director: Jack L. Wyszomierski	Management	For	For
2.	To ratify the selection by the Audit Committee of the Board of Directors of Ernst & Young LLP as Exelixis independent registered public accounting firm for the fiscal year ending December 28, 2018.	Management	For	For
3.	To approve, on an advisory basis, the compensation of Exelixis named executive officers, as disclosed in the accompanying Proxy Statement.	Management	For	For

### FIBROGEN, INC.

<b>Security Ticker Symbol Record Date</b>	31572Q808 FGEN 09-Apr-2018	<b>Meeting Type Meeting Date</b>	Annual 05-Jun-2018
-------------------------------------------	----------------------------------	----------------------------------	-----------------------

Item	Proposal	Proposed by	Vote	For/Against Management
1a.	Election of Class I Director: Thomas B. Neff	Management	For	For
1b.	Election of Class I Director: Jeffrey W. Henderson	Management	For	For
1c.	Election of Class I Director: James A. Schoeneck	Management	For	For
2.	To approve, on an advisory basis, the compensation of FibroGen s named executive officers, as disclosed in the proxy statement.	Management	For	For
3.	To ratify the selection of PricewaterhouseCoopers LLP by the Audit Committee of the Board of Directors as the independent registered public accounting firm of FibroGen for the year ending December 31, 2018.	Management	For	For

## FOAMIX PHARMACEUTICALS LTD

<b>Security</b>	M46135105	<b>Meeting Type</b>	Special
<b>Ticker Symbol</b>	FOMX	<b>Meeting Date</b>	27-Nov-2017
<b>Record Date</b>	25-Oct-2017		

Item	Proposal	Proposed by	Vote	For/Against Management
1.	(I) PAY MR. DOMZALSKI ANNUAL COMPENSATION OF \$440,000 FOR HIS SERVICES AS THE CHIEF EXECUTIVE OFFICER OF THE COMPANY, EFFECTIVE AS OF JULY 1, 2017, (II) APPROVE MR. DOMZALSKI S CASH BONUS FOR THE SIX MONTH PERIOD COMMENCING AS OF JULY 1, 2017 UP TO A MAXIMUM AMOUNT OF \$132,000, SUBJECT TO ...(DUE TO SPACE LIMITS, SEE PROXY STATEMENT FOR FULL PROPOSAL).	Management	For	For
1A.	DO YOU HAVE A PERSONAL INTEREST IN THE APPROVAL OF THIS PROPOSAL #1? MARK FOR = YES OR AGAINST = NO.	Management	Against	N/A
2.	AWARD MR. DOMZALSKI 327,720 OPTIONS AND 81,930 RSUS UNDER THE COMPANY S 2015 ISRAELI SHARE INCENTIVE PLAN AND ITS 2015 U.S. ADDENDUM.	Management	For	For
2A.	DO YOU HAVE A PERSONAL INTEREST IN THE APPROVAL OF THIS PROPOSAL #2? MARK FOR = YES OR AGAINST = NO.	Management	Against	N/A

## FOAMIX PHARMACEUTICALS LTD

<b>Security Ticker Symbol Record Date</b>	M46135105 FOMX 10-Apr-2018	<b>Meeting Type Meeting Date</b>	Annual 08-May-2018
-------------------------------------------	----------------------------------	----------------------------------	-----------------------

Item	Proposal	Proposed by	Vote	For/Against Management
1	Appoint Kesselman & Kesselman (a member firm of PricewaterhouseCoopers International Limited, or PwC) an independent registered public accounting firm, as the Company's independent public accountants for the fiscal year ending December 31, 2018, and authorize the Board (or the Audit Committee, if such authority is delegated to it by the Board) to fix the remuneration of such independent public accountants in accordance with the volume and nature of their services.	Management	For	For
2	Ratify the election of Mr. David Domzalski as a director of the Company.	Management	For	For
3	Approve the annual equity incentive awards to the Company's non-executive directors, as set out under Proposal 3 in the Company's proxy statement.	Management	For	For
4a	Approve the equity incentive grants to Mr. Domzalski for 2017, as set out under Proposal 4(a) in the Company's proxy statement.	Management	For	For
4a1	Please confirm you are a controlling shareholder/have a personal interest in the approval of Proposal 4(a)? If you vote FOR=YES or not at all your vote may not count for the Corresponding Proposal For= Yes, No=Against	Management	Against	N/A
4b	Approve the terms of Mr. Domzalski's cash bonus and equity compensation for 2018, as set out under Proposal 4(b) of the Company's proxy statement.	Management	For	For
4b1	Please confirm you are a controlling shareholder/have a personal interest in the approval of Proposal 4(b)? If you vote FOR=YES or not at all your vote may not count for the Corresponding Proposal For= Yes, No=Against	Management	Against	N/A
5a	Approve the 2016 equity conversion bonus for Dr. Tamarkin in respect of 2016, as set out under Proposal 5(a) of the Company's proxy statement	Management	For	For
5a1	Please confirm you are a controlling shareholder/have a personal interest in the approval of Proposal 5(a)? If you vote FOR=YES or not at all your vote may not count for the Corresponding Proposal For= Yes, No=Against	Management	Against	N/A
5b	Approve Dr. Tamarkin's cash bonus in respect of the first half of 2017, as set out under Proposal 5(b) of the Company's proxy statement.	Management	For	For
5b1	Please confirm you are a controlling shareholder/have a personal interest in the approval of Proposal 5(b)? If you vote FOR=YES or not at all your vote may not count for the Corresponding Proposal For= Yes, No=Against	Management	Against	N/A
6.	Approve the Company's Amended Compensation Policy, as set out under Proposal 6 of the Company's proxy statement.	Management	For	For
6a	Please confirm you are a controlling shareholder/have a personal interest in the approval of Proposal 6? If you vote FOR=YES or not at all your vote may not count for the	Management	Against	N/A



Corresponding Proposal For= Yes, No=Against

---

**FOUNDATION MEDICINE, INC.**

<b>Security</b>	350465100	<b>Meeting Type</b>	Annual
<b>Ticker Symbol</b>	FMI	<b>Meeting Date</b>	21-Jun-2018
<b>Record Date</b>	23-Apr-2018		

<b>Item</b>	<b>Proposal</b>	<b>Proposed by</b>	<b>Vote</b>	<b>For/Against Management</b>
1.	DIRECTOR	Management		
	1 Alexis Borisy		For	For
	2 Troy Cox		For	For
	3 Michael Dougherty		For	For
	4 Sandra Horning, M.D.		For	For
	5 Evan Jones		For	For
	6 Daniel O Day		For	For
	7 Michael Pellini, M.D.		For	For
	8 Michael Varney, Ph.D.		For	For
	9 Krishna Yeshwant, M.D.		For	For
2.	To ratify the appointment of KPMG LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2018.	Management	For	For

**GALAPAGOS N V**

<b>Security</b>	36315X101	<b>Meeting Type</b>	Annual
<b>Ticker Symbol</b>	GLPG	<b>Meeting Date</b>	24-Apr-2018
<b>Record Date</b>	20-Mar-2018		

<b>Item</b>	<b>Proposal</b>	<b>Proposed by</b>	<b>Vote</b>	<b>For/Against Management</b>
2.	Acknowledgement and approval of the non-consolidated annual accounts of the Company for the financial year ended on 31 December 2017 and approval of the allocation of the annual result as proposed by the board of directors.	Management	For	N/A
5.	Acknowledgement and approval of the remuneration report.	Management	For	N/A
6.	Release from liability to be granted to the directors and the statutory auditor for the performance of their duties in the course of the financial year ended 31 December 2017.	Management	For	N/A
7.1	Re-appointment of Dr. Werner Cautreels as director of the Company.	Management	For	N/A
7.2	Re-appointment of Mr. Howard Rowe as director of the Company.	Management	For	N/A
8.	Remuneration of directors.	Management	For	N/A
9.	Offer of warrants.	Management	For	N/A

**GENOMEDX BIOSCIENCES, INC.**

<b>Security</b>	N/A	<b>Meeting Type</b>	Special
<b>Ticker Symbol</b>	N/A	<b>Meeting Date</b>	20-Nov-2017
<b>Record Date</b>	N/A		

<b>Item</b>	<b>Proposal</b>	<b>Proposed by</b>	<b>Vote</b>	<b>For/Against Management</b>
1.	Authorized Share Structure Amendment Resolution	Management	For	For
2.	Special Rights and Restrictions Resolution	Management	For	For
3.	Class C Preferred Share Issuance Resolution	Management	For	For

**GENOMEDX BIOSCIENCES, INC.**

<b>Security</b>	N/A	<b>Meeting Type</b>	Special
<b>Ticker Symbol</b>	N/A	<b>Meeting Date</b>	8-Jan-2018
<b>Record Date</b>	N/A		

<b>Item</b>	<b>Proposal</b>	<b>Proposed by</b>	<b>Vote</b>	<b>For/Against Management</b>
1.	Non-shareholders as Proxyholders Resolution	Management	For	For
2.	Special Rights and Restrictions Resolution	Management	For	For

**GENOMEDX BIOSCIENCES, INC.**

<b>Security</b>	N/A	<b>Meeting Type</b>	Special
<b>Ticker Symbol</b>	N/A	<b>Meeting Date</b>	4-Feb-2018
<b>Record Date</b>	N/A		

<b>Item</b>	<b>Proposal</b>	<b>Proposed by</b>	<b>Vote</b>	<b>For/Against Management</b>
1.	Non-shareholders as Proxyholders Resolution	Management	For	For
2.	Authorized Share Structure Amendment Resolution	Management	For	For
3.	Articles Amendment Resolution	Management	For	For
4.	New Preferred Share Issuance Resolution	Management	For	For

**GENOMEDX BIOSCIENCES, INC.**

<b>Security</b>	N/A	<b>Meeting Type</b>	Special
<b>Ticker Symbol</b>	N/A	<b>Meeting Date</b>	31-Mar-2018
<b>Record Date</b>	N/A		

Edgar Filing: TEKLA HEALTHCARE INVESTORS - Form N-PX

Item	Proposal	Proposed by	Vote	For/Against Management
1.	Non-shareholders as Proxyholders Resolution	Management	For	For
2.	Authorized Share Structure Amendment Resolution	Management	For	For
3.	Articles Amendment Resolution	Management	For	For
4.	New Preferred Share Issuance Resolution	Management	For	For

**GENOMEDX BIOSCIENCES, INC.**

<b>Security</b>	N/A	<b>Meeting Type</b>	Special
<b>Ticker Symbol</b>	N/A	<b>Meeting Date</b>	29-Jun-2018
<b>Record Date</b>	N/A		

Item	Proposal	Proposed by	Vote	For/Against Management
1.	Non-shareholders as Proxyholders Resolution	Management	For	For
2.	Domestication Resolution	Management	For	For

---

Edgar Filing: TEKLA HEALTHCARE INVESTORS - Form N-PX

**GILEAD SCIENCES, INC.**

<b>Security</b>	375558103	<b>Meeting Type</b>	Annual
<b>Ticker Symbol</b>	GILD	<b>Meeting Date</b>	09-May-2018
<b>Record Date</b>	16-Mar-2018		

Item	Proposal	Proposed by	Vote	For/Against Management
1a.	Election of Director: John F. Cogan, Ph.D.	Management	For	For
1b.	Election of Director: Jacqueline K. Barton, Ph.D.	Management	For	For
1c.	Election of Director: Kelly A. Kramer	Management	For	For
1d.	Election of Director: Kevin E. Lofton	Management	For	For
1e.	Election of Director: John C. Martin, Ph.D.	Management	For	For
1f.	Election of Director: John F. Milligan, Ph.D.	Management	For	For
1g.	Election of Director: Richard J. Whitley, M.D.	Management	For	For
1h.	Election of Director: Gayle E. Wilson	Management	For	For
1i.	Election of Director: Per Wold-Olsen	Management	For	For
2.	To ratify the selection of Ernst & Young LLP by the Audit Committee of the Board of Directors as the independent registered public accounting firm of Gilead for the fiscal year ending December 31, 2018.	Management	For	For
3.	To approve, on an advisory basis, the compensation of our Named Executive Officers as presented in the Proxy Statement.	Management	For	For
4.	To vote on a stockholder proposal, if properly presented at the meeting, requesting that the Board adopt a policy that the Chairman of the Board of Directors be an independent director.	Shareholder	Against	For
5.	To vote on a stockholder proposal, if properly presented at the meeting, requesting that the Board take steps to permit stockholder action by written consent.	Shareholder	Against	For

**GLOBAL BLOOD THERAPEUTICS, INC.**

<b>Security</b>	37890U108	<b>Meeting Type</b>	Annual
<b>Ticker Symbol</b>	GBT	<b>Meeting Date</b>	20-Jun-2018
<b>Record Date</b>	23-Apr-2018		

Item	Proposal	Proposed by	Vote	For/Against Management
1.	DIRECTOR	Management		
	1	Scott W. Morrison	For	For
	2	Deval L. Patrick	For	For
	3	Mark L. Perry	For	For
2.	Approval, on a non-binding, advisory basis, of the compensation of the Company's named executive officers as disclosed in the proxy statement.	Management	For	For
3.	Recommendation, on a non-binding, advisory basis, of the preferred frequency of future advisory votes on the compensation of the Company's named executive officers.	Management	1 Year	For

Edgar Filing: TEKLA HEALTHCARE INVESTORS - Form N-PX

4.	Ratification of the appointment of KPMG LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2018.	Management	For	For
5.	Transaction of such other business as may properly come before the meeting or any adjournment or postponement thereof.	Management	For	For

---

## GW PHARMACEUTICALS PLC

<b>Security</b>	36197T103	<b>Meeting Type</b>	Annual
<b>Ticker Symbol</b>	GWPH	<b>Meeting Date</b>	14-Mar-2018
<b>Record Date</b>	05-Feb-2018		

Item	Proposal	Proposed by	Vote	For/Against Management
O1	TO RECEIVE, CONSIDER AND ADOPT THE DIRECTORS AND AUDITORS REPORTS AND STATEMENT OF ACCOUNTS FOR THE YEAR ENDED 30 SEPTEMBER 2017 AND NOTE THAT THE DIRECTORS DO NOT RECOMMEND PAYMENT OF A DIVIDEND	Management	For	N/A
O2	TO APPROVE THE DIRECTORS REMUNERATION REPORT	Management	For	N/A
O3	TO APPROVE THE DIRECTORS REMUNERATION POLICY	Management	For	N/A
O4	TO RE-ELECT JUSTIN GOVER AS A DIRECTOR	Management	For	N/A
O5	TO ELECT CATHERINE MACKEY AS A DIRECTOR	Management	For	N/A
O6	TO ELECT ALICIA SECOR AS A DIRECTOR	Management	For	N/A
O7	TO ELECT WILLIAM WALDEGRAVE AS A DIRECTOR	Management	For	N/A
O8	TO RE-APPOINT DELOITTE LLP AS AUDITOR	Management	For	N/A
O9	To authorise the Directors to determine the Auditor s remuneration	Management	For	N/A
O10	To authorise the Directors to allot shares pursuant to Section 551 of the Companies Act 2006 (the 2006 Act )	Management	For	N/A
S11	Subject to the passing of Resolution 10, to authorise the ...(due to space limits, see proxy material for full proposal).	Management	For	N/A
S12	To adopt new articles of association of the Company in ...(due to space limits, see proxy material for full proposal).	Management	For	N/A

Edgar Filing: TEKLA HEALTHCARE INVESTORS - Form N-PX

**HENRY SCHEIN, INC.**

<b>Security</b>	806407102	<b>Meeting Type</b>	Annual
<b>Ticker Symbol</b>	HSIC	<b>Meeting Date</b>	31-May-2018
<b>Record Date</b>	02-Apr-2018		

<b>Item</b>	<b>Proposal</b>	<b>Proposed by</b>	<b>Vote</b>	<b>For/Against Management</b>
1a.	Election of Director: Barry J. Alperin	Management	For	For
1b.	Election of Director: Gerald A. Benjamin	Management	For	For
1c.	Election of Director: Stanley M. Bergman	Management	For	For
1d.	Election of Director: James P. Breslawski	Management	For	For
1e.	Election of Director: Paul Brons	Management	For	For
1f.	Election of Director: Shira Goodman	Management	For	For
1g.	Election of Director: Joseph L. Herring	Management	For	For
1h.	Election of Director: Kurt P. Kuehn	Management	For	For
1i.	Election of Director: Philip A. Laskawy	Management	For	For
1j.	Election of Director: Anne H. Margulies	Management	For	For
1k.	Election of Director: Mark E. Mlotek	Management	For	For
1l.	Election of Director: Steven Paladino	Management	For	For
1m.	Election of Director: Carol Raphael	Management	For	For
1n.	Election of Director: E. Dianne Rekow, DDS, Ph.D.	Management	For	For
1o.	Election of Director: Bradley T. Sheares, Ph.D.	Management	For	For
2.	Proposal to amend the Company's Amended and Restated Certificate of Incorporation, as amended, to increase the number of authorized shares of common stock from 240,000,000 to 480,000,000.	Management	For	For
3.	Proposal to amend the Company's Amended and Restated Certificate of Incorporation, as amended, to add a forum selection clause.	Management	For	For
4.	Proposal to amend and restate the Company's Amended and Restated Certificate of Incorporation, as amended, to incorporate certain technical, administrative and updating changes as set forth in the Proxy Statement.	Management	For	For
5.	Proposal to approve, by non-binding vote, the 2017 compensation paid to the Company's Named Executive Officers.	Management	For	For
6.	Proposal to ratify the selection of BDO USA, LLP as the Company's independent registered public accounting firm for the fiscal year ending December 29, 2018.	Management	For	For

**HUMANA INC.**

<b>Security</b>	444859102	<b>Meeting Type</b>	Annual
<b>Ticker Symbol</b>	HUM	<b>Meeting Date</b>	19-Apr-2018
<b>Record Date</b>	26-Feb-2018		

<b>Item</b>	<b>Proposal</b>	<b>Proposed by</b>	<b>Vote</b>	<b>For/Against Management</b>
1a.	Election of Director: Kurt J. Hilzinger	Management	For	For



Edgar Filing: TEKLA HEALTHCARE INVESTORS - Form N-PX

1b.	Election of Director: Frank J. Bisignano	Management	For	For
1c.	Election of Director: Bruce D. Broussard	Management	For	For
1d.	Election of Director: Frank A. D. Amelio	Management	For	For
1e.	Election of Director: Karen B. DeSalvo, M.D.	Management	For	For
1f.	Election of Director: W. Roy Dunbar	Management	For	For
1g.	Election of Director: David A. Jones, Jr.	Management	For	For
1h.	Election of Director: William J. McDonald	Management	For	For
1i.	Election of Director: William E. Mitchell	Management	For	For
1j.	Election of Director: David B. Nash, M.D.	Management	For	For
1k.	Election of Director: James J. O'Brien	Management	For	For
1l.	Election of Director: Marissa T. Peterson	Management	For	For
2.	The ratification of the appointment of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm.	Management	For	For
3.	The approval of the compensation of the named executive officers as disclosed in the 2018 proxy statement.	Management	For	For

Edgar Filing: TEKLA HEALTHCARE INVESTORS - Form N-PX

**IDEXX LABORATORIES, INC.**

<b>Security</b>	45168D104	<b>Meeting Type</b>	Annual
<b>Ticker Symbol</b>	IDXX	<b>Meeting Date</b>	09-May-2018
<b>Record Date</b>	16-Mar-2018		

<b>Item</b>	<b>Proposal</b>	<b>Proposed by</b>	<b>Vote</b>	<b>For/Against Management</b>
1a.	Election of Director: Bruce L. Claflin	Management	For	For
1b.	Election of Director: Daniel M. Junius	Management	For	For
2.	Ratification of Appointment of Independent Registered Public Accounting Firm. To ratify the selection of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm for the current fiscal year.	Management	For	For
3.	Approval of the Adoption of the IDEXX Laboratories, Inc. 2018 Incentive Plan. To approve the Company's 2018 Stock Incentive Plan.	Management	For	For
4.	Advisory Vote on Executive Compensation. To approve a nonbinding advisory resolution on the Company's executive compensation.	Management	For	For

**ILLUMINA, INC.**

<b>Security</b>	452327109	<b>Meeting Type</b>	Annual
<b>Ticker Symbol</b>	ILMN	<b>Meeting Date</b>	23-May-2018
<b>Record Date</b>	29-Mar-2018		

<b>Item</b>	<b>Proposal</b>	<b>Proposed by</b>	<b>Vote</b>	<b>For/Against Management</b>
1a.	Election of Director: Jay T. Flatley	Management	For	For
1b.	Election of Director: John W. Thompson	Management	For	For
1c.	Election of Director: Gary S. Guthart, Ph.D.	Management	For	For
2.	To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 30, 2018.	Management	For	For
3.	To approve, on an advisory basis, the compensation of the named executive officers as disclosed in the Proxy Statement.	Management	For	For
4.	To approve, on an advisory basis, a stockholder proposal to elect each director annually.	Shareholder	Against	For

**ILLUMINOSS MEDICAL, INC.**

<b>Security</b>	N/A	<b>Meeting Type</b>	Written Consent
<b>Ticker Symbol</b>	N/A	<b>Meeting Date</b>	14-Nov-2017
<b>Record Date</b>	N/A		

Edgar Filing: TEKLA HEALTHCARE INVESTORS - Form N-PX

<b>Item</b>	<b>Proposal</b>	<b>Proposed by</b>	<b>Vote</b>	<b>For/Against Management</b>
1.	Sixth Amended and Restated Certificate of Incorporation	Management	For	For
2.	Convertible Note Financing	Management	For	For
3.	Amendment of March 2017 Notes and Warrants	Management	For	For
4.	Anti-Dilution	Management	For	For
5.	General Resolutions	Management	For	For

---

## INCYTE CORPORATION

<b>Security</b>	45337C102	<b>Meeting Type</b>	Annual
<b>Ticker Symbol</b>	INCY	<b>Meeting Date</b>	01-May-2018
<b>Record Date</b>	05-Mar-2018		

Item	Proposal	Proposed by	Vote	For/Against Management
1.1	Election of Director: Julian C. Baker	Management	For	For
1.2	Election of Director: Jean-Jacques Bienaime	Management	For	For
1.3	Election of Director: Paul A. Brooke	Management	For	For
1.4	Election of Director: Paul J. Clancy	Management	For	For
1.5	Election of Director: Wendy L. Dixon	Management	For	For
1.6	Election of Director: Jacquelyn A. Fouse	Management	For	For
1.7	Election of Director: Paul A. Friedman	Management	For	For
1.8	Election of Director: Herve Hoppenot	Management	For	For
2.	To approve, on a non-binding, advisory basis, the compensation of the Company's named executive officers.	Management	For	For
3.	To approve amendments to the Company's Amended and Restated 2010 Stock Incentive Plan.	Management	For	For
4.	To ratify the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for 2018.	Management	For	For

## INNOVIVA INC

<b>Security</b>	45781M101	<b>Meeting Type</b>	Annual
<b>Ticker Symbol</b>	INVA	<b>Meeting Date</b>	24-Apr-2018
<b>Record Date</b>	19-Mar-2018		

Item	Proposal	Proposed by	Vote	For/Against Management
1a.	Election of Director: George W. Bickerstaff, III	Management	For	For
1b.	Election of Director: Mark DiPaolo, Esq.	Management	For	For
1c.	Election of Director: Jules Haimovitz	Management	For	For
1d.	Election of Director: Odysseas D. Kostas, M.D.	Management	For	For
1e.	Election of Director: Sarah Schlesinger, M.D.	Management	For	For
2.	Approve the non-binding advisory resolution regarding executive compensation.	Management	For	For
3.	Ratify the selection by the Audit Committee of the Board of Directors for Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2018.	Management	For	For

## INTELLIA THERAPEUTICS, INC.

<b>Security</b>	45826J105	<b>Meeting Type</b>	Annual
-----------------	-----------	---------------------	--------

Edgar Filing: TEKLA HEALTHCARE INVESTORS - Form N-PX

**Ticker Symbol** NTLA **Meeting Date** 17-May-2018  
**Record Date** 04-Apr-2018

Item	Proposal	Proposed by	Vote	For/Against Management
1a.	Election of Class II Director: Frank Verwiel	Management	For	For
2.	Ratification of the appointment of Deloitte & Touche LLP as Intellia's independent registered public accounting firm for the fiscal year ending December 31, 2018.	Management	For	For

**IONIS PHARMACEUTICALS, INC.**

**Security** 462222100 **Meeting Type** Annual  
**Ticker Symbol** IONS **Meeting Date** 23-May-2018  
**Record Date** 26-Mar-2018

Item	Proposal	Proposed by	Vote	For/Against Management
1.	DIRECTOR	Management		
	1 Frederick T. Muto		For	For
	2 Breaux B. Castleman		For	For
2.	To approve, by non-binding vote, executive compensation.	Management	For	For
3.	Ratify the Audit Committee's selection of Ernst & Young LLP as independent auditors for the 2018 fiscal year.	Management	For	For

Edgar Filing: TEKLA HEALTHCARE INVESTORS - Form N-PX

**JAZZ PHARMACEUTICALS PLC**

<b>Security</b>	G50871105	<b>Meeting Type</b>	Annual
<b>Ticker Symbol</b>	JAZZ	<b>Meeting Date</b>	02-Aug-2018
<b>Record Date</b>	06-Jun-2018		

Item	Proposal	Proposed by	Vote	For/Against Management
1a.	Election of Director: Peter Gray	Management	For	For
1b.	Election of Director: Kenneth W. O Keefe	Management	For	For
1c.	Election of Director: Elmar Schnee	Management	For	For
1d.	Election of Director: Catherine A. Sohn	Management	For	For
2.	To ratify, on a non-binding advisory basis, the appointment of KPMG, Dublin as the independent auditors of Jazz Pharmaceuticals plc for the fiscal year ending December 31, 2018 and to authorize, in a binding vote, the board of directors, acting through the audit committee, to determine the independent auditors remuneration.	Management	For	For
3.	To approve, on a non-binding advisory basis, the compensation of Jazz Pharmaceuticals plc s named executive officers as disclosed in the proxy statement.	Management	For	For
4.	To indicate, on a non-binding advisory basis, the preferred frequency of the advisory vote on the compensation of Jazz Pharmaceuticals plc s named executive officers.	Management	1 Year	For

**JOHNSON & JOHNSON**

<b>Security</b>	478160104	<b>Meeting Type</b>	Annual
<b>Ticker Symbol</b>	JNJ	<b>Meeting Date</b>	26-Apr-2018
<b>Record Date</b>	27-Feb-2018		

Item	Proposal	Proposed by	Vote	For/Against Management
1a.	Election of Director: Mary C. Beckerle	Management	For	For
1b.	Election of Director: D. Scott Davis	Management	For	For
1c.	Election of Director: Ian E. L. Davis	Management	For	For
1d.	Election of Director: Jennifer A. Doudna	Management	For	For
1e.	Election of Director: Alex Gorsky	Management	For	For
1f.	Election of Director: Mark B. McClellan	Management	For	For
1g.	Election of Director: Anne M. Mulcahy	Management	For	For
1h.	Election of Director: William D. Perez	Management	For	For
1i.	Election of Director: Charles Prince	Management	For	For
1j.	Election of Director: A. Eugene Washington	Management	For	For
1k.	Election of Director: Ronald A. Williams	Management	For	For
2.	Advisory Vote to Approve Named Executive Officer Compensation	Management	For	For
3.	Ratification of Appointment of PricewaterhouseCoopers LLP as the Independent Registered Public Accounting Firm for 2018	Management	For	For
4.		Shareholder	Against	For

Edgar Filing: TEKLA HEALTHCARE INVESTORS - Form N-PX

Shareholder Proposal - Accounting for Litigation and Compliance in Executive Compensation Performance Measures

5.	Shareholder Proposal - Amendment to Shareholder Ability to Call Special Shareholder Meeting	Shareholder	Against	For
----	---------------------------------------------------------------------------------------------	-------------	---------	-----

**LEXICON PHARMACEUTICALS, INC.**

<b>Security Ticker Symbol Record Date</b>	528872302 LRRX 26-Feb-2018	<b>Meeting Type Meeting Date</b>	Annual 26-Apr-2018
-------------------------------------------	----------------------------------	----------------------------------	-----------------------

Item	Proposal	Proposed by	Vote	For/Against Management
1.	DIRECTOR	Management		
	1	Philippe J. Amouyal	For	For
	2	Lonnell Coats	For	For
	3	Frank P. Palantoni	For	For
2.	Advisory vote to approve the compensation paid to the Company's named executive officers.	Management	For	For
3.	Ratification and approval of the appointment of Ernst & Young LLP as Company's independent auditors for the fiscal year ending December 31, 2018.	Management	For	For

Edgar Filing: TEKLA HEALTHCARE INVESTORS - Form N-PX

**MERCK & CO., INC.**

<b>Security</b>	58933Y105	<b>Meeting Type</b>	Annual
<b>Ticker Symbol</b>	MRK	<b>Meeting Date</b>	22-May-2018
<b>Record Date</b>	28-Mar-2018		

Item	Proposal	Proposed by	Vote	For/Against Management
1a.	Election of Director: Leslie A. Brun	Management	For	For
1b.	Election of Director: Thomas R. Cech	Management	For	For
1c.	Election of Director: Pamela J. Craig	Management	For	For
1d.	Election of Director: Kenneth C. Frazier	Management	For	For
1e.	Election of Director: Thomas H. Glocer	Management	For	For
1f.	Election of Director: Rochelle B. Lazarus	Management	For	For
1g.	Election of Director: John H. Noseworthy	Management	For	For
1h.	Election of Director: Paul B. Rothman	Management	For	For
1i.	Election of Director: Patricia F. Russo	Management	For	For
1j.	Election of Director: Craig B. Thompson	Management	For	For
1k.	Election of Director: Inge G. Thulin	Management	For	For
1l.	Election of Director: Wendell P. Weeks	Management	For	For
1m.	Election of Director: Peter C. Wendell	Management	For	For
2.	Non-binding advisory vote to approve the compensation of our named executive officers.	Management	For	For
3.	Ratification of the appointment of the Company's independent registered public accounting firm for 2018.	Management	For	For
4.	Shareholder proposal concerning shareholders' right to act by written consent.	Shareholder	Against	For

**MILESTONE PHARMACEUTICALS, INC.**

<b>Security</b>	N/A	<b>Meeting Type</b>	Annual
<b>Ticker Symbol</b>	N/A	<b>Meeting Date</b>	27-Jun-2018
<b>Record Date</b>	N/A		

Item	Proposal	Proposed by	Vote	For/Against Management
1.	Acceptance of the Audited Financial Statements of the Corporation for year ended December 31, 2017	Management	For	For
2.	Election of Directors	Management	For	For
3.	Appointment of Auditors	Management	For	For
4.	Transaction of other Business	Management	For	For

**MOLECULAR TEMPLATES, INC.**

<b>Security</b>	608550109	<b>Meeting Type</b>	Annual
<b>Ticker Symbol</b>	MTEM	<b>Meeting Date</b>	31-May-2018
<b>Record Date</b>	10-Apr-2018		



Edgar Filing: TEKLA HEALTHCARE INVESTORS - Form N-PX

<b>Item</b>	<b>Proposal</b>	<b>Proposed by</b>	<b>Vote</b>	<b>For/Against Management</b>
1.	DIRECTOR			
	1	Jonathan Lanfear	For	For
	2	Scott Morenstein	For	For
2.	Approve the 2018 Equity Incentive Plan.	Management	For	For
3.	Ratify the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending 2018.	Management	For	For
4.	Approve by an advisory vote the compensation of our named executive officers, as disclosed in the accompanying proxy statement.	Management	For	For

Edgar Filing: TEKLA HEALTHCARE INVESTORS - Form N-PX

MYLAN N.V.

<b>Security</b>	N59465109	<b>Meeting Type</b>	Annual
<b>Ticker Symbol</b>	MYL	<b>Meeting Date</b>	29-Jun-2018
<b>Record Date</b>	01-Jun-2018		

Item	Proposal	Proposed by	Vote	For/Against Management
1A.	Appointment of Director: Heather Bresch	Management	For	For
1B.	Appointment of Director: Hon. Robert J. Cindrich	Management	For	For
1C.	Appointment of Director: Robert J. Coury	Management	For	For
1D.	Appointment of Director: JoEllen Lyons Dillon	Management	For	For
1E.	Appointment of Director: Neil Dimick, C.P.A.	Management	For	For
1F.	Appointment of Director: Melina Higgins	Management	For	For
1G.	Appointment of Director: Harry A. Korman	Management	For	For
1H.	Appointment of Director: Rajiv Malik	Management	For	For
1I.	Appointment of Director: Mark W. Parrish	Management	For	For
1J.	Appointment of Director: Pauline van der Meer Mohr	Management	For	For
1K.	Appointment of Director: Randall L. (Pete) Vanderveen, Ph.D.	Management	For	For
1L.	Appointment of Director: Sjoerd S. Vollebregt	Management	For	For
2.	Approval, on an advisory basis, of the compensation of the named executive officers of the Company	Management	For	For
3.	Adoption of the Dutch annual accounts for fiscal year 2017	Management	For	For
4.	Ratification of the selection of Deloitte & Touche LLP as the Company's independent registered public accounting firm for fiscal year 2018	Management	For	For
5.	Instruction to Deloitte Accountants B.V. for the audit of the Company's Dutch statutory annual accounts for fiscal year 2018	Management	For	For
6.	Authorization of the Board to acquire shares in the capital of the Company	Management	For	For

MYOVANT SCIENCES LTD.

<b>Security</b>	G637AM102	<b>Meeting Type</b>	Annual
<b>Ticker Symbol</b>	MYOV	<b>Meeting Date</b>	18-Aug-2017
<b>Record Date</b>	14-Jul-2017		

Item	Proposal	Proposed by	Vote	For/Against Management
1.1	ELECTION OF CLASS I DIRECTOR: MARK ALTMAYER	Management	For	For
1.2	ELECTION OF CLASS I DIRECTOR: TERRIE CURRAN	Management	For	For
1.3	ELECTION OF CLASS I DIRECTOR: KEITH MANCHESTER, M.D.	Management	For	For
2.	TO RATIFY THE SELECTION BY THE AUDIT COMMITTEE OF THE BOARD OF ERNST & YOUNG LLP AS MYOVANT'S INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR MYOVANT'S	Management	For	For

Edgar Filing: TEKLA HEALTHCARE INVESTORS - Form N-PX

FISCAL YEAR ENDING MARCH 31, 2018, TO  
APPOINT ERNST & YOUNG LLP AS AUDITOR FOR  
STATUTORY PURPOSES UNDER THE BERMUDA  
COMPANIES ACT 1981, AS AMENDED, FOR  
MYOVANT S...(DUE TO SPACE LIMITS, SEE PROXY  
STATEMENT FOR FULL PROPOSAL).

---

## MYOVANT SCIENCES LTD.

<b>Security</b>	G637AM102	<b>Meeting Type</b>	Special
<b>Ticker Symbol</b>	MYOV	<b>Meeting Date</b>	09-Feb-2018
<b>Record Date</b>	22-Jan-2018		

Item	Proposal	Proposed by	Vote	For/Against Management
1.	To approve an amendment to our Bye-laws to declassify the Board of Directors.	Management	For	For
2.	To approve an amendment to our Bye-laws to modify shareholder proposal and nomination procedures.	Management	For	For
3.	To approve an amendment to our Bye-laws to eliminate all supermajority voting requirements.	Management	For	For
4.	To approve an amendment to our Bye-laws to modify certain director removal and vacancy requirements.	Management	For	For
5.	To approve an amendment to our Bye-laws to revise certain other provisions in our Bye-laws.	Management	For	For

## NATERA, INC.

<b>Security</b>	632307104	<b>Meeting Type</b>	Annual
<b>Ticker Symbol</b>	NTRA	<b>Meeting Date</b>	16-May-2018
<b>Record Date</b>	26-Mar-2018		

Item	Proposal	Proposed by	Vote	For/Against Management
1.	DIRECTOR	Management		
	1 Roelof F. Botha		For	For
	2 Todd Cozzens		For	For
	3 Matthew Rabinowitz		For	For
2.	Proposal to ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2018.	Management	For	For

## NEKTAR THERAPEUTICS

<b>Security</b>	640268108	<b>Meeting Type</b>	Annual
<b>Ticker Symbol</b>	NKTR	<b>Meeting Date</b>	26-Jun-2018
<b>Record Date</b>	27-Apr-2018		

Item	Proposal	Proposed by	Vote	For/Against Management
1a.	Election of Director: Jeff Ajer	Management	For	For
1b.	Election of Director: Robert B. Chess	Management	For	For
1c.	Election of Director: Roy A. Whitfield	Management	For	For

## Edgar Filing: TEKLA HEALTHCARE INVESTORS - Form N-PX

2.	To approve an amendment and restatement of the 2017 Performance Incentive Plan to increase the aggregate number of shares of common stock authorized for issuance under the 2017 Performance Incentive Plan by 10,900,000 shares to a total reserve of 19,200,000 shares.	Management	For	For
3.	To ratify the selection of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2018.	Management	For	For
4.	To approve a non-binding advisory resolution regarding our executive compensation (a say-on-pay vote).	Management	For	For

---

**NEUROCRINE BIOSCIENCES, INC.**

<b>Security</b>	64125C109	<b>Meeting Type</b>	Annual
<b>Ticker Symbol</b>	NBIX	<b>Meeting Date</b>	24-May-2018
<b>Record Date</b>	29-Mar-2018		

Item	Proposal	Proposed by	Vote	For/Against Management
1.	DIRECTOR	Management		
	1	William H Rastetter PhD	For	For
	2	George J. Morrow	For	For
2.	Advisory vote to approve the compensation paid to the Company's named executive officers.	Management	For	For
3.	To approve an amendment to the Company's 2011 Equity Incentive Plan to increase the number of shares of common stock reserved for issuance thereunder from 17,000,000 to 19,000,000.	Management	For	For
4.	To approve the Company's 2018 Employee Stock Purchase Plan.	Management	Against	Against
5.	To ratify the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2018.	Management	For	For

**NEVRO CORP.**

<b>Security</b>	64157F103	<b>Meeting Type</b>	Annual
<b>Ticker Symbol</b>	NVRO	<b>Meeting Date</b>	21-May-2018
<b>Record Date</b>	28-Mar-2018		

Item	Proposal	Proposed by	Vote	For/Against Management
1.	DIRECTOR	Management		
	1	Brad Vale, Ph.D., DVM	For	For
	2	Michael DeMane	For	For
	3	Lisa D. Earnhardt	For	For
2.	To ratify the selection, by the Audit Committee of the Company's Board of Directors, of PricewaterhouseCoopers LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2018	Management	For	For
3.	To approve, on a non-binding advisory basis, the compensation of the named executive officers as disclosed in the Company's proxy statement in accordance with the compensation disclosure rules of the Securities and Exchange Commission	Management	For	For

**NEWLINK GENETICS CORPORATION**

<b>Security</b>	651511107	<b>Meeting Type</b>	Annual
<b>Ticker Symbol</b>	NLNK	<b>Meeting Date</b>	23-May-2018
<b>Record Date</b>	26-Mar-2018		

Edgar Filing: TEKLA HEALTHCARE INVESTORS - Form N-PX

<b>Item</b>	<b>Proposal</b>	<b>Proposed by</b>	<b>Vote</b>	<b>For/Against Management</b>
1.	DIRECTOR			
	1	Chad A. Johnson	For	For
	2	Ernest J. Talarico, III	For	For
	3	Lota S. Zoth	For	For
2.	To approve, on an advisory basis, the compensation of the Company's named executive officers, as disclosed in the proxy statement.	Management	For	For
3.	To indicate, on an advisory basis, the preferred frequency of future advisory votes on the compensation of our named executive officers.	Management	1 Year	For
4.	To ratify the selection, by the Audit Committee of the Board of Directors, of KPMG LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2018.	Management	For	For

## NUCANA PLC

<b>Security Ticker Symbol Record Date</b>	67022C106 NCNA 24-May-2018	<b>Meeting Type Meeting Date</b>	Annual 27-Jun-2018
-------------------------------------------	----------------------------------	----------------------------------	-----------------------

Item	Proposal	Proposed by	Vote	For/Against Management
O1	To re-elect (as a Class III director) Isaac Cheng, who is retiring in accordance with the Articles of Association of the Company, as a director of the Company.	Management	For	N/A
O2	To re-elect (as a Class III director) Martin Mellish, who is retiring by rotation in accordance with the Articles of Association of the Company, as a director of the Company.	Management	For	N/A
O3	To re-elect (as a Class III director) Adam George, who is retiring by rotation in accordance with the Articles of Association of the Company, as a director of the Company.	Management	For	N/A
O4	To elect (as a Class II director) Cyrille Leperlier, who is standing for election for the remaining portion of his term of office, as a director of the Company.	Management	For	N/A
O5	To re-appoint Ernst & Young LLP as auditors of the Company to hold office from the conclusion of this meeting until the conclusion of the next annual general meeting of the Company.	Management	For	N/A
O6	To authorise the directors to determine the remuneration of the auditors of the Company.	Management	For	N/A
O7	To receive the Company's audited accounts for the financial year ended 31 December 2017, together with the strategic report, directors' report and auditors' report on those accounts.	Management	For	N/A
O8	To receive and approve the Directors' Remuneration Report (other than the part containing the Directors' Remuneration Policy) for the financial year ended 31 December 2017.	Management	For	N/A
O9	To receive and approve the Directors' Remuneration Policy, such policy to take effect from the date on which this resolution is passed.	Management	For	N/A
O10	That the directors be generally and unconditionally authorised pursuant to Section 551 of the Companies Act 2006 (the Act) to exercise all the powers of the Company to allot shares in the Company or grant rights to subscribe for or to convert any security into shares in the Company up to an aggregate nominal amount of GBP 640,000. This authority shall, unless previously renewed, revoked or varied by the Company in general meeting, expire on the conclusion of the annual general meeting ...(due to space limits, see proxy material for full proposal).	Management	For	N/A
S11	That, subject to the passing of resolution 10, the directors be empowered pursuant to Section 570 of the Act to allot equity securities (as defined in Section 560 of the Act) for cash under the authority given by that resolution as if Section 561 (1) of the Act did not apply to any such allotment, provided that such authority shall be limited to the allotment of equity securities up to a nominal amount of GBP 640,000, such authority to expire on the conclusion of the annual general ...(due to space limits, see proxy	Management	For	N/A



material for full proposal).

---

## OVID THERAPEUTICS INC.

<b>Security</b>	690469101	<b>Meeting Type</b>	Annual
<b>Ticker Symbol</b>	OVID	<b>Meeting Date</b>	06-Jun-2018
<b>Record Date</b>	11-Apr-2018		

Item	Proposal	Proposed by	Vote	For/Against Management
1.	DIRECTOR	Management		
	1	Douglas Williams	For	For
	2	Barbara Duncan	For	For
2.	Ratification of the selection of the independent registered public accounting firm.	Management	For	For

## PFIZER INC.

<b>Security</b>	717081103	<b>Meeting Type</b>	Annual
<b>Ticker Symbol</b>	PFE	<b>Meeting Date</b>	26-Apr-2018
<b>Record Date</b>	27-Feb-2018		

Item	Proposal	Proposed by	Vote	For/Against Management
1a.	Election of Director: Dennis A. Ausiello	Management	For	For
1b.	Election of Director: Ronald E. Blaylock	Management	For	For
1c.	Election of Director: Albert Bourla	Management	For	For
1d.	Election of Director: W. Don Cornwell	Management	For	For
1e.	Election of Director: Joseph J. Echevarria	Management	For	For
1f.	Election of Director: Helen H. Hobbs	Management	For	For
1g.	Election of Director: James M. Kilts	Management	For	For
1h.	Election of Director: Dan R. Littman	Management	For	For
1i.	Election of Director: Shantanu Narayen	Management	For	For
1j.	Election of Director: Suzanne Nora Johnson	Management	For	For
1k.	Election of Director: Ian C. Read	Management	For	For
1l.	Election of Director: James C. Smith	Management	For	For
2.	Ratify the selection of KPMG LLP as independent registered public accounting firm for 2018	Management	For	For
3.	2018 Advisory approval of executive compensation	Management	For	For
4.	Approval of the Pfizer Inc. French Sub-Plan under the 2014 Stock Plan	Management	For	For
5.	Shareholder proposal regarding right to act by written consent	Shareholder	Against	For
6.	Shareholder proposal regarding independent chair policy	Shareholder	Against	For
7.	Shareholder proposal regarding report on lobbying activities	Shareholder	Against	For

**PIERIS PHARMACEUTICALS, INC.**

<b>Security</b>	720795103	<b>Meeting Type</b>	Annual
<b>Ticker Symbol</b>	PIRS	<b>Meeting Date</b>	24-Jul-2018
<b>Record Date</b>	25-May-2018		

Item	Proposal	Proposed by	Vote	For/Against Management
1.	DIRECTOR	Management		
	1	Christopher P. Kiritsy	For	For
	2	Jean-Pierre Bizzari	For	For
2.	Approve the Company's 2018 Employee, Director and Consultant Equity Incentive Plan.	Management	For	For
3.	Approve the Company's 2018 Employee Stock Purchase Plan.	Management	For	For
4.	Ratify the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2018.	Management	For	For

**PORTOLA PHARMACEUTICALS, INC.**

<b>Security</b>	737010108	<b>Meeting Type</b>	Annual
<b>Ticker Symbol</b>	PTLA	<b>Meeting Date</b>	08-Jun-2018
<b>Record Date</b>	12-Apr-2018		

Item	Proposal	Proposed by	Vote	For/Against Management
1.	DIRECTOR	Management		
	1	Dennis Fenton, Ph.D.	For	For
	2	Charles Homcy, M.D.	For	For
	3	David C. Stump, M.D.	For	For
2.	To approve an amendment to the Company's Amended and Restated Certificate of Incorporation, as amended, to increase the authorized number of shares of common stock from 100,000,000 to 150,000,000 shares.	Management	For	For
3.	To approve, on an advisory basis, the compensation of the Company's named executive officers, as disclosed in this proxy statement.	Management	For	For
4.	To ratify the selection of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2018.	Management	For	For

**PRA HEALTH SCIENCES, INC.**

<b>Security</b>	69354M108	<b>Meeting Type</b>	Annual
<b>Ticker Symbol</b>	PRAH	<b>Meeting Date</b>	31-May-2018
<b>Record Date</b>	05-Apr-2018		

Edgar Filing: TEKLA HEALTHCARE INVESTORS - Form N-PX

Item	Proposal	Proposed by	Vote	For/Against Management
1.	DIRECTOR			
	1	Max C. Lin	For	For
	2	Matthew P. Young	For	For
2.	To ratify the appointment of Deloitte & Touche LLP as the Company's independent registered public accounting firm for 2018.	Management	For	For
3.	Approval, in a non-binding advisory vote, of the compensation paid to the Company's named executive officers.	Management	For	For
4.	Approval of the PRA Health Sciences, Inc. 2018 Stock Incentive Plan.	Management	For	For

---

**PROTAGONIST THERAPEUTICS INC**

<b>Security</b>	74366E102	<b>Meeting Type</b>	Annual
<b>Ticker Symbol</b>	PTGX	<b>Meeting Date</b>	29-May-2018
<b>Record Date</b>	09-Apr-2018		

Item	Proposal	Proposed by	Vote	For/Against Management
1.	DIRECTOR	Management		
	1	Chaitan Khosla, Ph.D.	For	For
	2	William D. Waddill	For	For
	3	Lewis T Williams MD PhD	For	For
2.	To ratify the selection by the Audit Committee of the Board of PricewaterhouseCoopers LLP as Protagonist Therapeutics independent registered public accounting firm for the fiscal year ending December 31, 2018.	Management	For	For

**PTC THERAPEUTICS, INC.**

<b>Security</b>	69366J200	<b>Meeting Type</b>	Annual
<b>Ticker Symbol</b>	PTCT	<b>Meeting Date</b>	13-Jun-2018
<b>Record Date</b>	20-Apr-2018		

Item	Proposal	Proposed by	Vote	For/Against Management
1.	DIRECTOR	Management		
	1	Michael Schmertzler	For	For
	2	G D Steele Jr., MD, PhD	For	For
2.	Ratification of the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2018.	Management	For	For
3.	Advisory vote to approve named executive officer compensation.	Management	For	For

**RA PHARMACEUTICALS, INC.**

<b>Security</b>	74933V108	<b>Meeting Type</b>	Annual
<b>Ticker Symbol</b>	RARX	<b>Meeting Date</b>	28-Jun-2018
<b>Record Date</b>	30-Apr-2018		

Item	Proposal	Proposed by	Vote	For/Against Management
1.	DIRECTOR	Management		
	1	Robert Heft, Ph.D.	For	For
	2	Rajeev Shah	For	For
2.	To ratify the appointment of Deloitte & Touche LLP as our independent registered public accounting firm for the fiscal year	Management	For	For

Edgar Filing: TEKLA HEALTHCARE INVESTORS - Form N-PX

ending December 31, 2018.

**REGENERON PHARMACEUTICALS, INC.**

<b>Security</b>	75886F107	<b>Meeting Type</b>	Annual
<b>Ticker Symbol</b>	REGN	<b>Meeting Date</b>	08-Jun-2018
<b>Record Date</b>	12-Apr-2018		

<b>Item</b>	<b>Proposal</b>	<b>Proposed by</b>	<b>Vote</b>	<b>For/Against Management</b>
1.1	Election of Director: Arthur F. Ryan	Management	For	For
1.2	Election of Director: George L. Sing	Management	For	For
1.3	Election of Director: Marc Tessier-Lavigne	Management	For	For
2.	Ratification of the appointment of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2018.	Management	For	For

---

## SAGE THERAPEUTICS, INC.

<b>Security</b>	78667J108	<b>Meeting Type</b>	Annual
<b>Ticker Symbol</b>	SAGE	<b>Meeting Date</b>	06-Jun-2018
<b>Record Date</b>	09-Apr-2018		

Item	Proposal	Proposed by	Vote	For/Against Management
1.	DIRECTOR	Management		
	1	Geno Germano	For	For
	2	Steven Paul	For	For
2.	To ratify the appointment of PricewaterhouseCoopers LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2018.	Management	For	For
3.	Approve, on an advisory basis, the compensation of the named executive officers.	Management	For	For

## SAREPTA THERAPEUTICS INC.

<b>Security</b>	803607100	<b>Meeting Type</b>	Annual
<b>Ticker Symbol</b>	SRPT	<b>Meeting Date</b>	06-Jun-2018
<b>Record Date</b>	11-Apr-2018		

Item	Proposal	Proposed by	Vote	For/Against Management
1A	ELECTION OF GROUP I DIRECTOR: Michael W. Bonney	Management	For	For
1B	ELECTION OF GROUP I DIRECTOR: Douglas S. Ingram	Management	For	For
1C	ELECTION OF GROUP I DIRECTOR: Hans Wigzell, M.D., Ph.D.	Management	For	For
2.	ADVISORY VOTE TO APPROVE, ON A NON-BINDING BASIS, NAMED EXECUTIVE OFFICER COMPENSATION	Management	For	For
3.	APPROVAL OF THE COMPANY'S 2018 EQUITY INCENTIVE PLAN	Management	For	For
4.	RATIFICATION OF KPMG LLP AS INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE YEAR ENDING DECEMBER 31, 2018	Management	For	For

## SEATTLE GENETICS, INC.

<b>Security</b>	812578102	<b>Meeting Type</b>	Annual
<b>Ticker Symbol</b>	SGEN	<b>Meeting Date</b>	18-May-2018
<b>Record Date</b>	22-Mar-2018		

Edgar Filing: TEKLA HEALTHCARE INVESTORS - Form N-PX

Item	Proposal	Proposed by	Vote	For/Against Management
1.	DIRECTOR			
	1	Clay B. Siegall	For	For
	2	Felix Baker	For	For
	3	Nancy A. Simonian	For	For
2.	To ratify the appointment of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2018.	Management	For	For
3.	To approve the amendment and restatement of the Seattle Genetics, Inc. Amended and Restated 2007 Equity and Incentive Plan to, among other changes, increase the aggregate number of shares of common stock authorized for issuance thereunder by 6,000,000.	Management	For	For
4.	Advisory vote to approve the compensation of the Company's named executive officers as disclosed in the Company's proxy statement.	Management	For	For



## SHIRE PLC

<b>Security Ticker Symbol Record Date</b>	82481R106 SHPG 22-Mar-2018	<b>Meeting Type Meeting Date</b>	Annual 24-Apr-2018
-------------------------------------------	----------------------------------	----------------------------------	-----------------------

Item	Proposal	Proposed by	Vote	For/Against Management
1.	To receive the Company's Annual Report and Accounts for the year ended December 31, 2017.	Management	For	For
2.	To approve the Directors' Remuneration Report, excluding the Directors' Remuneration Policy, set out on pages 78 to 108 of the Annual Report and Accounts for the year ended December 31, 2017.	Management	For	For
3.	To approve the Directors' Remuneration Policy, contained within the Directors' Remuneration Report and set out on pages 86 to 95 of the Annual Report and Accounts for the year ended December 31, 2017, to take effect after the end of the Annual General Meeting on April 24, 2018.	Management	For	For
4.	To re-elect Olivier Bohuon as a Director.	Management	For	For
5.	To re-elect Ian Clark as a Director.	Management	For	For
6.	To elect Thomas Dittrich as a Director.	Management	For	For
7.	To re-elect Gail Fosler as a Director.	Management	For	For
8.	To re-elect Steven Gillis as a Director.	Management	For	For
9.	To re-elect David Ginsburg as a Director.	Management	For	For
10.	To re-elect Susan Kilsby as a Director.	Management	For	For
11.	To re-elect Sara Mathew as a Director.	Management	For	For
12.	To re-elect Flemming Ornskov as a Director.	Management	For	For
13.	To re-elect Albert Stroucken as a Director.	Management	For	For
14.	To re-appoint Deloitte LLP as the Company's Auditor until the conclusion of the next Annual General Meeting of the Company.	Management	For	For
15.	To authorize the Audit, Compliance & Risk Committee to determine the remuneration of the Auditor.	Management	For	For
16.	That the authority to allot Relevant Securities (as defined in the Company's Articles of Association (the "Articles")) conferred on the Directors by Article 10 paragraph (B) of the Articles be renewed and for this purpose the Authorised Allotment Amount shall be: (a) GBP 15,187,600.85 of Relevant Securities. (b) solely in connection with an allotment pursuant to an offer by way of a Rights Issue (as defined in the Articles, but only if and to the extent that such offer is ...(due to space limits, see proxy material for full proposal).	Management	For	For
17.	That, subject to the passing of Resolution 16, the authority to allot equity securities (as defined in the Company's Articles of Association (the "Articles")) wholly for cash conferred on the Directors by Article 10 paragraph (D) of the Articles be renewed and for this purpose the Non Pre-emptive Amount (as defined in the Articles) shall be GBP 2,278,140.10 and the Allotment Period shall be the period commencing on April 24, 2018, and ending on the earlier of the close of business on ...(due to space limits, see proxy material for full proposal).	Management	For	For
18.		Management	For	For

Edgar Filing: TEKLA HEALTHCARE INVESTORS - Form N-PX

That, subject to the passing of Resolutions 16 and 17 and for the purpose of the authority to allot equity securities (as defined in the Company's Articles of Association (the Articles)) wholly for cash conferred on the Directors by Article 10 paragraph (D) of the Articles and renewed by Resolution 17, the Non Pre-emptive Amount (as defined in the Articles) shall be increased from GBP 2,278,140.10 to GBP ...(due to space limits, see proxy material for full proposal).

19.	That the Company be and is hereby generally and unconditionally authorized: (a) pursuant to Article 57 of the Companies (Jersey) Law 1991 to make market purchases of Ordinary Shares in the capital of the Company, provided that: (1) the maximum number of Ordinary Shares hereby authorized to be purchased is 91,125,605; (2) the minimum price, exclusive of any expenses, which may be paid for an Ordinary Share is five pence; (3) the maximum price, exclusive of any expenses, which may be paid ...(due to space limits, see proxy material for full proposal).	Management	For	For
20.	To approve that a general meeting of the Company, other than an annual general meeting, may be called on not less than 14 clear days' notice.	Management	For	For

Edgar Filing: TEKLA HEALTHCARE INVESTORS - Form N-PX

TELIGENT, INC.

<b>Security</b>	87960W104	<b>Meeting Type</b>	Annual
<b>Ticker Symbol</b>	TLGT	<b>Meeting Date</b>	21-May-2018
<b>Record Date</b>	29-Mar-2018		

Item	Proposal	Proposed by	Vote	For/Against Management
1.	DIRECTOR	Management		
	1	Carole S. Ben-Maimon	For	For
	2	John Celentano	For	For
	3	Bhaskar Chaudhuri	For	For
	4	James C. Gale	For	For
	5	Jason Grenfell-Gardner	For	For
	6	Steven Koehler	For	For
	7	Thomas J. Sabatino, Jr.	For	For
2.	Approve an amendment to the Teligent, Inc. 2016 Equity Incentive Plan to increase the number of shares of common stock reserved thereunder for issuance from 2,000,000 shares to a total of 4,000,000 shares.	Management	For	For
3.	To ratify the selection of EisnerAmper LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2018.	Management	For	For
4.	To approve by an advisory vote the compensation of the Company's named executive officers as disclosed in the proxy statement.	Management	For	For

TESARO INC

<b>Security</b>	881569107	<b>Meeting Type</b>	Annual
<b>Ticker Symbol</b>	TSRO	<b>Meeting Date</b>	10-May-2018
<b>Record Date</b>	13-Mar-2018		

Item	Proposal	Proposed by	Vote	For/Against Management
1.	DIRECTOR	Management		
	1	Leon O. Moulder, Jr.	For	For
	2	Mary Lynne Hedley, Ph.D	For	For
	3	David M. Mott	For	For
	4	Lawrence M. Alleva	For	For
	5	James O. Armitage, M.D.	For	For
	6	Earl M. Collier, Jr.	For	For
	7	Garry A. Nicholson	For	For
	8	Kavita Patel, M.D.	For	For
	9	Beth Seidenberg, M.D.	For	For
	10	Pascale Witz	For	For
2.	To approve the Tesaro, Inc., Non-Employee Director Compensation Policy, including compensation amounts for 2018.	Management	For	For
3.	To approve, by non-binding vote, the Company's executive compensation.	Management	For	For
4.		Management	For	For

Edgar Filing: TEKLA HEALTHCARE INVESTORS - Form N-PX

To approve an amendment to the Tesaro, Inc., 2012 Employee Stock Purchase Plan to, among other things, increase the number of shares available for issuance thereunder by 275,000 shares.

5.	To ratify the appointment of Ernst & Young, LLP as the independent registered public accounting firm for the Company for the fiscal year ending December 31, 2018.	Management	For	For
----	--------------------------------------------------------------------------------------------------------------------------------------------------------------------	------------	-----	-----

---

**TETRAPHASE PHARMACEUTICALS, INC.**

<b>Security</b>	88165N105	<b>Meeting Type</b>	Annual
<b>Ticker Symbol</b>	TTPH	<b>Meeting Date</b>	30-May-2018
<b>Record Date</b>	06-Apr-2018		

<b>Item</b>	<b>Proposal</b>	<b>Proposed by</b>	<b>Vote</b>	<b>For/Against Management</b>
1.	DIRECTOR	Management		
	1 Jeffrey Chodakewitz		For	For
	2 Gerri Henwood		For	For
	3 Guy Macdonald		For	For
2.	To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2018.	Management	For	For
3.	To approve, on a non-binding advisory basis, the compensation of our named executive officers.	Management	For	For

**TEVA PHARMACEUTICAL INDUSTRIES LIMITED**

<b>Security</b>	881624209	<b>Meeting Type</b>	Annual
<b>Ticker Symbol</b>	TEVA	<b>Meeting Date</b>	05-Jun-2018
<b>Record Date</b>	26-Apr-2018		

<b>Item</b>	<b>Proposal</b>	<b>Proposed by</b>	<b>Vote</b>	<b>For/Against Management</b>
1.1	Election of Director: Rosemary A. Crane	Management	For	For
1.2	Election of Director: Gerald M. Lieberman	Management	For	For
1.3	Election of Director: Professor Ronit Satchi-Fainaro	Management	For	For
2.	To approve, on a non-binding advisory basis, the compensation for Teva's named executive officers.	Management	For	For
3.	To recommend, on a non-binding advisory basis, to hold a non-binding advisory vote to approve the compensation for Teva's named executive officers every one, two or three years.	Management	1 Year	For
4.	To appoint Kesselman & Kesselman, a member of PricewaterhouseCoopers International Ltd., as Teva's independent registered public accounting firm until the 2019 annual meeting of shareholders.	Management	For	For
5.	To approve an amendment and restatement of Teva's 2008 Employee Stock Purchase Plan for U.S. Employees.	Management	For	For

**THE MEDICINES COMPANY**

<b>Security</b>	584688105	<b>Meeting Type</b>	Annual
<b>Ticker Symbol</b>	MDCO	<b>Meeting Date</b>	31-May-2018
<b>Record Date</b>	13-Apr-2018		

Edgar Filing: TEKLA HEALTHCARE INVESTORS - Form N-PX

<b>Item</b>	<b>Proposal</b>	<b>Proposed by</b>	<b>Vote</b>	<b>For/Against Management</b>
1A.	Election of Director: Alexander J. Denner	Management	For	For
1B.	Election of Director: Fredric N. Eshelman	Management	For	For
1C.	Election of Director: Geno J. Germano	Management	For	For
1D.	Election of Director: John C. Kelly	Management	For	For
1E.	Election of Director: Clive A. Meanwell	Management	For	For
1F.	Election of Director: Paris Panayiotopoulos	Management	For	For
1G.	Election of Director: Sarah J. Schlesinger	Management	For	For
2.	Approve an amendment to our 2013 stock incentive plan in order to increase the number of shares of common stock authorized for issuance under the plan by 5,000,000 shares.	Management	For	For
3.	Approve, in an advisory vote, the compensation of our named executive officers as presented in the proxy statement.	Management	For	For
4.	Ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2018.	Management	For	For

Edgar Filing: TEKLA HEALTHCARE INVESTORS - Form N-PX

**THERAPEUTICSMD, INC.**

<b>Security</b>	88338N107	<b>Meeting Type</b>	Annual
<b>Ticker Symbol</b>	TXMD	<b>Meeting Date</b>	25-Jun-2018
<b>Record Date</b>	26-Apr-2018		

Item	Proposal	Proposed by	Vote	For/Against Management
1.	DIRECTOR	Management		
	1 Tommy G. Thompson		For	For
	2 Robert G. Finizio		For	For
	3 John C.K. Milligan, IV		For	For
	4 Brian Bernick		For	For
	5 J. Martin Carroll		For	For
	6 Cooper C. Collins		For	For
	7 Robert V. LaPenta, Jr.		For	For
	8 Jules A. Musing		For	For
	9 Angus C. Russell		For	For
	10 Jane F. Barlow		For	For
	11 Nicholas Segal		For	For
2.	To approve, on a non-binding advisory basis, the compensation of our named executive officers for the fiscal year ended December 31, 2017 (say-on-pay).	Management	For	For
3.	To ratify the appointment of Grant Thornton LLP, an independent registered public accounting firm, as the independent auditor of our company for the fiscal year ending December 31, 2018.	Management	For	For

**THERMO FISHER SCIENTIFIC INC.**

<b>Security</b>	883556102	<b>Meeting Type</b>	Annual
<b>Ticker Symbol</b>	TMO	<b>Meeting Date</b>	23-Mar-2018
<b>Record Date</b>	28-Mar-2018		

Item	Proposal	Proposed by	Vote	For/Against Management
1A.	Election of Director: Marc N. Casper	Management	For	For
1B.	Election of Director: Nelson J. Chai	Management	For	For
1C.	Election of Director: C. Martin Harris	Management	For	For
1D.	Election of Director: Tyler Jacks	Management	For	For
1E.	Election of Director: Judy C. Lewent	Management	For	For
1F.	Election of Director: Thomas J. Lynch	Management	For	For
1G.	Election of Director: Jim P. Manzi	Management	For	For
1H.	Election of Director: Lars R. Sorensen	Management	For	For
1I.	Election of Director: Scott M. Sperling	Management	For	For
1J.	Election of Director: Elaine S. Ullian	Management	For	For
1K.	Election of Director: Dion J. Weisler	Management	For	For
2.	An advisory vote to approve named executive officer compensation.	Management	For	For
3.	Ratification of the Audit Committee's selection of PricewaterhouseCoopers LLP as the Company's independent auditors for 2018.	Management	For	For

## THEROX, INC.

<b>Security</b>	N/A	<b>Meeting Type</b>	Written Consent
<b>Ticker Symbol</b>	N/A	<b>Meeting Date</b>	24-Apr-2018
<b>Record Date</b>	N/A		

<b>Item</b>	<b>Proposal</b>	<b>Proposed by</b>	<b>Vote</b>	<b>For/Against Management</b>
1.	Approval of Second Certificate of Amendment to Eleventh Amended and Restated Certificate of Incorporation	Management	For	For
2.	Waiver of Participation Rights in Note Transaction	Management	For	For
3.	Approval of Amendment to Fourth Amended and Restated Investors Rights and Voting Agreement	Management	For	For
4.	Approval of Option Agreement with ZOLL	Management	For	For
5.	Approval of Agreement and Plan of Merger	Management	For	For
6.	Appointment of Shareholder Representative Services, LLC as Representative	Management	For	For
7.	Appointment of Representative Advisory Group Members	Shareholder	Against	For
8.	Ratification of Shadow Preferred Stock Issuance	Shareholder	Against	For
9.	General Authority	Shareholder	Against	For

---



**TRILLIUM THERAPEUTICS INC.**

<b>Security</b>	89620X506	<b>Meeting Type</b>	Annual and Special Meeting
<b>Ticker Symbol</b>	TRIL	<b>Meeting Date</b>	01-Jun-2018
<b>Record Date</b>	20-Apr-2018		

Item	Proposal	Proposed by	Vote	For/Against Management
1	DIRECTOR	Management		
	1	Mr. Luke Beshar	For	For
	2	Dr. Robert Kirkman	For	For
	3	Dr. Michael Moore	For	For
	4	Dr. Thomas Reynolds	For	For
	5	Dr. Niclas Stiernholm	For	For
	6	Dr. Calvin Stiller	For	For
	7	Dr. Helen Tayton-Martin	For	For
2	To reappoint Ernst & Young, LLP, Chartered Professional Accountants, Licensed Public Accountants, as auditors of the Corporation for the ensuing year and to authorize the directors to fix the remuneration to be paid to the auditors.	Management	For	For
3	Consider and, if deemed appropriate, approve the Corporation's amended and restated stock option plan, all as more particularly set out in the management information circular prepared by the Corporation in respect of the Meeting.	Management	Against	Against

**ULTRAGENYX PHARMACEUTICAL INC.**

<b>Security</b>	90400D108	<b>Meeting Type</b>	Annual
<b>Ticker Symbol</b>	RARE	<b>Meeting Date</b>	19-Jun-2018
<b>Record Date</b>	23-Apr-2018		

Item	Proposal	Proposed by	Vote	For/Against Management
1a.	Election of Director: Deborah Dunsire, M.D.	Management	For	For
1b.	Election of Director: Michael Narachi	Management	For	For
1c.	Election of Director: Clay B. Siegall, Ph.D.	Management	For	For
2.	Ratification of the selection of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2018.	Management	For	For
3.	Advisory (non-binding) vote to approve the compensation of our named executive officers.	Management	For	For

**UNITED THERAPEUTICS CORPORATION**

<b>Security</b>	91307C102	<b>Meeting Type</b>	Annual
<b>Ticker Symbol</b>	UTHR	<b>Meeting Date</b>	26-Jun-2018
<b>Record Date</b>	30-Apr-2018		

Edgar Filing: TEKLA HEALTHCARE INVESTORS - Form N-PX

<b>Item</b>	<b>Proposal</b>	<b>Proposed by</b>	<b>Vote</b>	<b>For/Against Management</b>
1a.	Election of Director: Katherine Klein	Management	For	For
1b.	Election of Director: Ray Kurzweil	Management	For	For
1c.	Election of Director: Martine Rothblatt	Management	For	For
1d.	Election of Director: Louis Sullivan	Management	For	For
2.	Advisory resolution to approve executive compensation.	Management	For	For
3.	Approval of the amendment and restatement of the United Therapeutics Corporation 2015 Stock Incentive Plan.	Management	For	For
4.	Ratification of the appointment of Ernst & Young LLP as United Therapeutics Corporation's independent registered public accounting firm for 2018.	Management	For	For

## UNITEDHEALTH GROUP INCORPORATED

<b>Security</b>	91324P102	<b>Meeting Type</b>	Annual
<b>Ticker Symbol</b>	UNH	<b>Meeting Date</b>	04-Jun-2018
<b>Record Date</b>	10-Apr-2018		

Item	Proposal	Proposed by	Vote	For/Against Management
1a.	Election of Director: William C. Ballard, Jr.	Management	For	For
1b.	Election of Director: Richard T. Burke	Management	For	For
1c.	Election of Director: Timothy P. Flynn	Management	For	For
1d.	Election of Director: Stephen J. Hemsley	Management	For	For
1e.	Election of Director: Michele J. Hooper	Management	For	For
1f.	Election of Director: F. William McNabb III	Management	For	For
1g.	Election of Director: Valerie C. Montgomery Rice, M.D.	Management	For	For
1h.	Election of Director: Glenn M. Renwick	Management	For	For
1i.	Election of Director: Kenneth I. Shine, M.D.	Management	For	For
1j.	Election of Director: David S. Wichmann	Management	For	For
1k.	Election of Director: Gail R. Wilensky, Ph.D.	Management	For	For
2.	Advisory approval of the Company's executive compensation.	Management	For	For
3.	Ratification of the appointment of Deloitte & Touche LLP as the independent registered public accounting firm for the Company for the year ending December 31, 2018.	Management	For	For

## VERTEX PHARMACEUTICALS INCORPORATED

<b>Security</b>	92532F100	<b>Meeting Type</b>	Annual
<b>Ticker Symbol</b>	VRTX	<b>Meeting Date</b>	17-May-2018
<b>Record Date</b>	29-Mar-2018		

Item	Proposal	Proposed by	Vote	For/Against Management
1.1	Election of Class I Director: Sangeeta N. Bhatia	Management	For	For
1.2	Election of Class I Director: Jeffrey M. Leiden	Management	For	For
1.3	Election of Class I Director: Bruce I. Sachs	Management	For	For
2.	Amendments to our charter and by-laws to eliminate supermajority provisions.	Management	For	For
3.	Amendment and restatement of our 2013 Stock and Option Plan, to among other things, increase the number of shares available under the plan by 8.0 million shares.	Management	For	For
4.	Ratification of Ernst & Young LLP as our Independent Registered Public Accounting firm for the year ending December 31, 2018.	Management	For	For
5.	Advisory vote on named executive officer compensation.	Management	For	For
6.	Shareholder proposal, if properly presented at the meeting, requesting that we prepare a report on the risks to us of rising drug prices.	Shareholder	Against	For
7.	Shareholder proposal, if properly presented at the meeting, requesting that we prepare a report on our policies and activities with respect to lobbying.	Shareholder	Against	For



**SIGNATURES**

Pursuant to the requirements of the Investment Company Act of 1940, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

(Registrant)	Tekla Healthcare Investors
By (Signature and Title)*	/s/ Daniel R. Omstead (Daniel R. Omstead, President)
Date	8/20/18

---

\*Print the name and title of each signing officer under his or her signature.